<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="generate">
            <roleset id="generate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="agent, causer&#x09;&#x09;//gene, process//&#x0A;" />
                    <role n="1" descr="thing created&#x09;&#x09;&#x0A;" />
                </roles>
                <example src="ARCHIVE" no="0">
                    <text>A transcription start site is located approximately 4 kilobases 5 to the translation codon, and an RNA splice of 3863 bases occurring in the 5-untranslated region generated mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="ARCHIVE" no="1">
                    <text>A transcription start site is located approximately 4 kilobases 5 to the translation codon, and an RNA splice of 3863 bases occurring in the 5-untranslated region generates mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="ARCHIVE" no="2">
                    <text>A transcription start site is located approximately 4 kilobases 5 to the translation codon, and an RNA splice of 3863 bases occurs in the 5-untranslated region to generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="ARCHIVE" no="3">
                    <text>A transcription start site is located approximately 4 kilobases 5 to the translation codon, and mature HeLa cell mRNA has been generated by an RNA splice of 3863 bases occurring in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="ARCHIVE" no="4">
                    <text>A transcription start site is located approximately 4 kilobases 5 to the translation codon, and mature HeLa cell mRNA is generated by an RNA splice of 3863 bases occurring in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="ARCHIVE" no="5">
                    <text>A transcription start site is located approximately 4 kilobases 5 to the translation codon, and mature HeLa cell mRNA was generated by an RNA splice of 3863 bases occurring in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="ARCHIVE" no="6">
                    <text>A transcription start site is located approximately 4 kilobases 5 to the translation codon, and mature HeLa cell mRNA will be generated by an RNA splice of 3863 bases occurring in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="ARCHIVE" no="7">
                    <text>Human leukocyte antigen (HLA)-G molecules are generated by an alternative splicing of the primary transcript of the gene and display specialized function in regulating the immune response.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="ARCHIVE" no="8">
                    <text>Human leukocyte antigen (HLA)-G molecules have been generated by an alternative splicing of the primary transcript of the gene and have displayed specialized function in regulating the immune response.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="ARCHIVE" no="9">
                    <text>Human leukocyte antigen (HLA)-G molecules were generated by an alternative splicing of the primary transcript of the gene and displayed specialized function in regulating the immune response.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="ARCHIVE" no="10">
                    <text>Human leukocyte antigen (HLA)-G molecules will be generated by an alternative splicing of the primary transcript of the gene and will display specialized function in regulating the immune response.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="ARCHIVE" no="11">
                    <text>In addition, the AR N-terminus generated a functional interaction surface, since its deletion abolished FHL2 binding.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="ARCHIVE" no="12">
                    <text>In addition, the AR N-terminus generates a functional interaction surface, since its deletion abolishes FHL2 binding.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="ARCHIVE" no="13">
                    <text>In addition, the AR N-terminus is required to generate a functional interaction surface, since its deletion abolishes FHL2 binding.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="ARCHIVE" no="14">
                    <text>In addition, the AR N-terminus, whose deletion abolishes FHL2 binding, generates a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="ARCHIVE" no="15">
                    <text>In addition, the AR N-terminus, whose deletion had abolished FHL2 binding, generated a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="ARCHIVE" no="16">
                    <text>Prnd generates major transcripts of 1.7 and 2.7 kb as well as some unusual chimeric transcripts generated by intergenic splicing with Prnp.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="ARCHIVE" no="17">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a have been generated by mutating amino acids EE (437 and 438) to AA.FLAG epitope has been added to the C-terminus of Stat5aEE-AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="ARCHIVE" no="18">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a is generated by mutating amino acids EE (437 and 438) to AA.FLAG epitope is added to the C-terminus of Stat5aEE-AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="ARCHIVE" no="19">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a was generated by mutating amino acids EE (437 and 438) to AA.FLAG epitope was added to the C-terminus of Stat5aEE-AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="ARCHIVE" no="20">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a will be generated by mutating amino acids EE (437 and 438) to AA.FLAG epitope will be added to the C-terminus of Stat5aEE-AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="ARCHIVE" no="21">
                    <text>We report results from preliminary transcription microarray experiments that revealed two previously unknown members of the NarL regulon: the aspA gene encoding aspartate-ammonia lyase being able to generate fumarate; and the dcuSR operon encoding the dicarboxylate-responsive regulatory system.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="ARCHIVE" no="22">
                    <text>We report results from preliminary transcription microarray experiments that revealed two previously unknown members of the NarL regulon: the aspA gene encoding aspartate-ammonia lyase generating fumarate; and the dcuSR operon encoding the dicarboxylate-responsive regulatory system.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="ARCHIVE" no="23">
                    <text>We report results from preliminary transcription microarray experiments that revealed two previously unknown members of the NarL regulon: the aspA gene encoding aspartate-ammonia lyase which generates fumarate; and the dcuSR operon encoding the dicarboxylate-responsive regulatory system.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="ARCHIVE" no="24">
                    <text>We report results from preliminary transcription microarray experiments that revealed two previously unknown members of the NarL regulon: the aspA gene encoding aspartate-ammonia lyase which has generated fumarate; and the dcuSR operon encoding the dicarboxylate-responsive regulatory system.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="ARCHIVE" no="25">
                    <text>We report results from preliminary transcription microarray experiments that revealed two previously unknown members of the NarL regulon: the aspA gene encoding aspartate-ammonia lyase, which generates fumarate; and the dcuSR operon encoding the dicarboxylate-responsive regulatory system.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="ARCHIVE" no="26">
                    <text>a functional interaction surface is generated by the AR N-terminus whose deletion abolishes FHL2 binding.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="ARCHIVE" no="27">
                    <text>a functional interaction surface was generated by the AR N-terminus, because the AR N-terminuss deletion abolishes FHL2 binding.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="ARCHIVE" no="28">
                    <text>an alternative splicing of the primary transcript of the gene generated Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="ARCHIVE" no="29">
                    <text>an alternative splicing of the primary transcript of the gene generates Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="ARCHIVE" no="30">
                    <text>intergenic splicing with Prnp generate some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="ARCHIVE" no="31">
                    <text>intergenic splicing with Prnp has generated some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="ARCHIVE" no="32">
                    <text>mutating amino acids EE (437 and 438) to AA are able to generate the DNA-binding mutant (Stat5aEE-AA) of Stat5a.FLAG epitope was added to the C-terminus of Stat5aEE-AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="ARCHIVE" no="33">
                    <text>mutating amino acids EE (437 and 438) to AA can generate the DNA-binding mutant (Stat5aEE-AA) of Stat5a.FLAG epitope was added to the C-terminus of Stat5aEE-AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="ARCHIVE" no="34">
                    <text>mutating amino acids EE (437 and 438) to AA generate the DNA-binding mutant (Stat5aEE-AA) of Stat5a.FLAG epitope was added to the C-terminus of Stat5aEE-AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="ARCHIVE" no="35">
                    <text>mutating amino acids EE (437 and 438) to AA generated the DNA-binding mutant (Stat5aEE-AA) of Stat5a.FLAG epitope was added to the C-terminus of Stat5aEE-AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="ARCHIVE" no="36">
                    <text>some unusual chimeric transcripts are generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="ARCHIVE" no="37">
                    <text>some unusual chimeric transcripts have been generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="ARCHIVE" no="38">
                    <text>some unusual chimeric transcripts may be generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="ARCHIVE" no="39">
                    <text>some unusual chimeric transcripts were generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="ARCHIVE" no="40">
                    <text>some unusual chimeric transcripts will be generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Abeta peptides (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Abeta peptides (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Abeta peptides are generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Abeta peptides is generated by proteolysis of the amyloid precursor proteins (APP) within the recombinational synapse.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Abeta peptides is generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Abeta peptides was generated by proteolysis of the amyloid precursor proteins (APP) within the recombinational synapse.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Abeta peptides was generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Abeta peptides were generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Abeta peptides has been generated by proteolysis of the amyloid precursor proteins (APP)</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Abeta peptides is generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Abeta peptides was generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Abeta peptides will be generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that NO reacts anaerobically with the Fe-S cluster of purified FNR generated spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that NO reacts anaerobically with the Fe-S cluster of purified FNR generates spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that NO reacts anaerobically with the Fe-S cluster of purified FNR is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Prnd generated major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Prnd generates major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Prnd is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The TBC method generated sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The TBC method generates sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The TBC method is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The bidentate RNase III Dicer generated the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The bidentate RNase III Dicer generates the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The bidentate RNase III Dicer is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a DNase I hypersensitive has been generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a DNase I hypersensitive is generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a DNase I hypersensitive was generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a DNase I hypersensitive will be generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro has been generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro is generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro was generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro will be generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a higher order protein-DNA complex has been generated by this binding</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a higher order protein-DNA complex is generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a higher order protein-DNA complex was generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a higher order protein-DNA complex will be generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a monoclonal antibody against FHL2 has been generated by us</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a monoclonal antibody against FHL2 has been generated by we</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a monoclonal antibody against FHL2 is generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a monoclonal antibody against FHL2 is generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a monoclonal antibody against FHL2 was generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a monoclonal antibody against FHL2 was generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a monoclonal antibody against FHL2 will be generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a monoclonal antibody against FHL2 will be generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that degradation generated specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that degradation generates specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that degradation is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarase B generated fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarase B generates fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarase B is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarate has been generated by fumarase B</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarate is generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarate was generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarate will be generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that major transcripts of 1.7 and 2.7 kb has been generated by Prnd</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that major transcripts of 1.7 and 2.7 kb is generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that major transcripts of 1.7 and 2.7 kb was generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that major transcripts of 1.7 and 2.7 kb will be generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that nNOS generated superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that nNOS generates superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that nNOS is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that proteolysis of the amyloid precursor proteins (APP) generated Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that proteolysis of the amyloid precursor proteins (APP) generates Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that proteolysis of the amyloid precursor proteins (APP) is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that sequential overlapping fragments has been generated by The TBC method</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that sequential overlapping fragments is generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that sequential overlapping fragments was generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that sequential overlapping fragments will be generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that specific fragments has been generated by degradation</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that specific fragments is generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that specific fragments was generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that specific fragments will be generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex has been generated by NO reacts anaerobically with the Fe-S cluster of purified FNR</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex is generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex was generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex will be generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that superoxide has been generated by nNOS</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that superoxide is generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that superoxide was generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that superoxide will be generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the 21-23 nt long mature RNAs has been generated by The bidentate RNase III Dicer</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the 21-23 nt long mature RNAs is generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the 21-23 nt long mature RNAs was generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the 21-23 nt long mature RNAs will be generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that this binding generated a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that this binding generates a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that this binding is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that us generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that us generates a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that us is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that we generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that we generates a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that we is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) can generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) cleaves microRNA precursors to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro within the recombinational synapse.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro within the recombinational synapse.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) has generated a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) has generated a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is able to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) may generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) was optimized to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), generating a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro are not generated by degradation.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro have not been generated by degradation.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro were not generated by degradation.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro will not be generated by degradation.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that degradation did not generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that degradation does not generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of L723 in H3, although again the relatively small fraction involved and the possibility that degradation did not generate the correct three-dimensional interaction surface or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of L723 in H3, although again the relatively small fraction involved and the possibility that degradation does not generate the correct three-dimensional interaction surface or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of L723 in H3, although again the relatively small fraction involved and the possibility that the correct three-dimensional interaction surface are not generated by degradation.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of L723 in H3, although again the relatively small fraction involved and the possibility that the correct three-dimensional interaction surface have not been generated by degradation.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of L723 in H3, although again the relatively small fraction involved and the possibility that the correct three-dimensional interaction surface were not generated by degradation.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of L723 in H3, although again the relatively small fraction involved and the possibility that the correct three-dimensional interaction surface will not be generated by degradation.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of NO reacts anaerobically with the Fe-S cluster of purified FNR, although again the relatively small fraction involved and the possibility that degradation did not generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of NO reacts anaerobically with the Fe-S cluster of purified FNR, although again the relatively small fraction involved and the possibility that degradation does not generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of NO reacts anaerobically with the Fe-S cluster of purified FNR, although again the relatively small fraction involved and the possibility that spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex are not generated by degradation.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of NO reacts anaerobically with the Fe-S cluster of purified FNR, although again the relatively small fraction involved and the possibility that spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex have not been generated by degradation.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of NO reacts anaerobically with the Fe-S cluster of purified FNR, although again the relatively small fraction involved and the possibility that spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex were not generated by degradation.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of NO reacts anaerobically with the Fe-S cluster of purified FNR, although again the relatively small fraction involved and the possibility that spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex will not be generated by degradation.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of Prnd, although again the relatively small fraction involved and the possibility that degradation did not generate major transcripts of 1.7 and 2.7 kb or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of Prnd, although again the relatively small fraction involved and the possibility that degradation does not generate major transcripts of 1.7 and 2.7 kb or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of Prnd, although again the relatively small fraction involved and the possibility that major transcripts of 1.7 and 2.7 kb are not generated by degradation.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of Prnd, although again the relatively small fraction involved and the possibility that major transcripts of 1.7 and 2.7 kb have not been generated by degradation.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of Prnd, although again the relatively small fraction involved and the possibility that major transcripts of 1.7 and 2.7 kb were not generated by degradation.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of Prnd, although again the relatively small fraction involved and the possibility that major transcripts of 1.7 and 2.7 kb will not be generated by degradation.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The TBC method, although again the relatively small fraction involved and the possibility that degradation did not generate sequential overlapping fragments or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The TBC method, although again the relatively small fraction involved and the possibility that degradation does not generate sequential overlapping fragments or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The TBC method, although again the relatively small fraction involved and the possibility that sequential overlapping fragments are not generated by degradation.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The TBC method, although again the relatively small fraction involved and the possibility that sequential overlapping fragments have not been generated by degradation.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The TBC method, although again the relatively small fraction involved and the possibility that sequential overlapping fragments were not generated by degradation.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The TBC method, although again the relatively small fraction involved and the possibility that sequential overlapping fragments will not be generated by degradation.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The bidentate RNase III Dicer, although again the relatively small fraction involved and the possibility that degradation did not generate the 21-23 nt long mature RNAs or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The bidentate RNase III Dicer, although again the relatively small fraction involved and the possibility that degradation does not generate the 21-23 nt long mature RNAs or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The bidentate RNase III Dicer, although again the relatively small fraction involved and the possibility that the 21-23 nt long mature RNAs are not generated by degradation.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The bidentate RNase III Dicer, although again the relatively small fraction involved and the possibility that the 21-23 nt long mature RNAs have not been generated by degradation.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The bidentate RNase III Dicer, although again the relatively small fraction involved and the possibility that the 21-23 nt long mature RNAs were not generated by degradation.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of The bidentate RNase III Dicer, although again the relatively small fraction involved and the possibility that the 21-23 nt long mature RNAs will not be generated by degradation.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that a DNase I hypersensitive are not generated by degradation.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that a DNase I hypersensitive have not been generated by degradation.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that a DNase I hypersensitive were not generated by degradation.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that a DNase I hypersensitive will not be generated by degradation.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that degradation did not generate a DNase I hypersensitive or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), although again the relatively small fraction involved and the possibility that degradation does not generate a DNase I hypersensitive or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of fumarase B, although again the relatively small fraction involved and the possibility that degradation did not generate fumarate or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of fumarase B, although again the relatively small fraction involved and the possibility that degradation does not generate fumarate or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of fumarase B, although again the relatively small fraction involved and the possibility that fumarate are not generated by degradation.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of fumarase B, although again the relatively small fraction involved and the possibility that fumarate have not been generated by degradation.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of fumarase B, although again the relatively small fraction involved and the possibility that fumarate were not generated by degradation.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of fumarase B, although again the relatively small fraction involved and the possibility that fumarate will not be generated by degradation.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of nNOS, although again the relatively small fraction involved and the possibility that degradation did not generate superoxide or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of nNOS, although again the relatively small fraction involved and the possibility that degradation does not generate superoxide or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of nNOS, although again the relatively small fraction involved and the possibility that superoxide are not generated by degradation.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of nNOS, although again the relatively small fraction involved and the possibility that superoxide have not been generated by degradation.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of nNOS, although again the relatively small fraction involved and the possibility that superoxide were not generated by degradation.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of nNOS, although again the relatively small fraction involved and the possibility that superoxide will not be generated by degradation.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of proteolysis of the amyloid precursor proteins (APP), although again the relatively small fraction involved and the possibility that Abeta peptides are not generated by degradation.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of proteolysis of the amyloid precursor proteins (APP), although again the relatively small fraction involved and the possibility that Abeta peptides have not been generated by degradation.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of proteolysis of the amyloid precursor proteins (APP), although again the relatively small fraction involved and the possibility that Abeta peptides were not generated by degradation.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of proteolysis of the amyloid precursor proteins (APP), although again the relatively small fraction involved and the possibility that Abeta peptides will not be generated by degradation.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of proteolysis of the amyloid precursor proteins (APP), although again the relatively small fraction involved and the possibility that degradation did not generate Abeta peptides or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of proteolysis of the amyloid precursor proteins (APP), although again the relatively small fraction involved and the possibility that degradation does not generate Abeta peptides or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of this binding, although again the relatively small fraction involved and the possibility that a higher order protein-DNA complex are not generated by degradation.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of this binding, although again the relatively small fraction involved and the possibility that a higher order protein-DNA complex have not been generated by degradation.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of this binding, although again the relatively small fraction involved and the possibility that a higher order protein-DNA complex were not generated by degradation.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of this binding, although again the relatively small fraction involved and the possibility that a higher order protein-DNA complex will not be generated by degradation.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of this binding, although again the relatively small fraction involved and the possibility that degradation did not generate a higher order protein-DNA complex or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of this binding, although again the relatively small fraction involved and the possibility that degradation does not generate a higher order protein-DNA complex or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of us, although again the relatively small fraction involved and the possibility that a monoclonal antibody against FHL2 are not generated by degradation.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of us, although again the relatively small fraction involved and the possibility that a monoclonal antibody against FHL2 have not been generated by degradation.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of us, although again the relatively small fraction involved and the possibility that a monoclonal antibody against FHL2 were not generated by degradation.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of us, although again the relatively small fraction involved and the possibility that a monoclonal antibody against FHL2 will not be generated by degradation.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of us, although again the relatively small fraction involved and the possibility that degradation did not generate a monoclonal antibody against FHL2 or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of us, although again the relatively small fraction involved and the possibility that degradation does not generate a monoclonal antibody against FHL2 or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that a monoclonal antibody against FHL2 are not generated by degradation.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that a monoclonal antibody against FHL2 have not been generated by degradation.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that a monoclonal antibody against FHL2 were not generated by degradation.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that a monoclonal antibody against FHL2 will not be generated by degradation.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation did not generate a monoclonal antibody against FHL2 or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation does not generate a monoclonal antibody against FHL2 or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>In the absence of L-arginine, Abeta peptides (O(2)-) has been generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>In the absence of L-arginine, Abeta peptides (O(2)-) is generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>In the absence of L-arginine, Abeta peptides (O(2)-) was generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>In the absence of L-arginine, Abeta peptides (O(2)-) will be generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>In the absence of L-arginine, EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro (O(2)-).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>In the absence of L-arginine, EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro (O(2)-).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>In the absence of L-arginine, EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) has been shown to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro (O(2)-).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>In the absence of L-arginine, L723 in H3 generated the correct three-dimensional interaction surface (O(2)-).</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>In the absence of L-arginine, L723 in H3 generates the correct three-dimensional interaction surface (O(2)-).</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>In the absence of L-arginine, L723 in H3 has been shown to generate the correct three-dimensional interaction surface (O(2)-).</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>In the absence of L-arginine, NO reacts anaerobically with the Fe-S cluster of purified FNR generated spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex (O(2)-).</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>In the absence of L-arginine, NO reacts anaerobically with the Fe-S cluster of purified FNR generates spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex (O(2)-).</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>In the absence of L-arginine, NO reacts anaerobically with the Fe-S cluster of purified FNR has been shown to generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex (O(2)-).</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>In the absence of L-arginine, Prnd generated major transcripts of 1.7 and 2.7 kb (O(2)-).</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>In the absence of L-arginine, Prnd generates major transcripts of 1.7 and 2.7 kb (O(2)-).</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>In the absence of L-arginine, Prnd has been shown to generate major transcripts of 1.7 and 2.7 kb (O(2)-).</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>In the absence of L-arginine, The TBC method generated sequential overlapping fragments (O(2)-).</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>In the absence of L-arginine, The TBC method generates sequential overlapping fragments (O(2)-).</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>In the absence of L-arginine, The TBC method has been shown to generate sequential overlapping fragments (O(2)-).</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>In the absence of L-arginine, The bidentate RNase III Dicer generated the 21-23 nt long mature RNAs (O(2)-).</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>In the absence of L-arginine, The bidentate RNase III Dicer generates the 21-23 nt long mature RNAs (O(2)-).</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>In the absence of L-arginine, The bidentate RNase III Dicer has been shown to generate the 21-23 nt long mature RNAs (O(2)-).</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>In the absence of L-arginine, a DNase I hypersensitive (O(2)-) has been generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>In the absence of L-arginine, a DNase I hypersensitive (O(2)-) is generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>In the absence of L-arginine, a DNase I hypersensitive (O(2)-) was generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>In the absence of L-arginine, a DNase I hypersensitive (O(2)-) will be generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>In the absence of L-arginine, a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro (O(2)-) has been generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>In the absence of L-arginine, a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro (O(2)-) is generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>In the absence of L-arginine, a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro (O(2)-) was generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>In the absence of L-arginine, a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro (O(2)-) will be generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>In the absence of L-arginine, a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive (O(2)-).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>In the absence of L-arginine, a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive (O(2)-).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>In the absence of L-arginine, a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) has been shown to generate a DNase I hypersensitive (O(2)-).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>In the absence of L-arginine, a higher order protein-DNA complex (O(2)-) has been generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>In the absence of L-arginine, a higher order protein-DNA complex (O(2)-) is generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>In the absence of L-arginine, a higher order protein-DNA complex (O(2)-) was generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>In the absence of L-arginine, a higher order protein-DNA complex (O(2)-) will be generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>In the absence of L-arginine, a monoclonal antibody against FHL2 (O(2)-) has been generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>In the absence of L-arginine, a monoclonal antibody against FHL2 (O(2)-) has been generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>In the absence of L-arginine, a monoclonal antibody against FHL2 (O(2)-) is generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>In the absence of L-arginine, a monoclonal antibody against FHL2 (O(2)-) is generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>In the absence of L-arginine, a monoclonal antibody against FHL2 (O(2)-) was generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>In the absence of L-arginine, a monoclonal antibody against FHL2 (O(2)-) was generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>In the absence of L-arginine, a monoclonal antibody against FHL2 (O(2)-) will be generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>In the absence of L-arginine, a monoclonal antibody against FHL2 (O(2)-) will be generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>In the absence of L-arginine, degradation generated specific fragments (O(2)-).</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>In the absence of L-arginine, degradation generates specific fragments (O(2)-).</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>In the absence of L-arginine, degradation has been shown to generate specific fragments (O(2)-).</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>In the absence of L-arginine, fumarase B generated fumarate (O(2)-).</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>In the absence of L-arginine, fumarase B generates fumarate (O(2)-).</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>In the absence of L-arginine, fumarase B has been shown to generate fumarate (O(2)-).</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>In the absence of L-arginine, fumarate (O(2)-) has been generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>In the absence of L-arginine, fumarate (O(2)-) is generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>In the absence of L-arginine, fumarate (O(2)-) was generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>In the absence of L-arginine, fumarate (O(2)-) will be generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>In the absence of L-arginine, major transcripts of 1.7 and 2.7 kb (O(2)-) has been generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>In the absence of L-arginine, major transcripts of 1.7 and 2.7 kb (O(2)-) is generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>In the absence of L-arginine, major transcripts of 1.7 and 2.7 kb (O(2)-) was generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>In the absence of L-arginine, major transcripts of 1.7 and 2.7 kb (O(2)-) will be generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>In the absence of L-arginine, proteolysis of the amyloid precursor proteins (APP) generated Abeta peptides (O(2)-).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>In the absence of L-arginine, proteolysis of the amyloid precursor proteins (APP) generates Abeta peptides (O(2)-).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>In the absence of L-arginine, proteolysis of the amyloid precursor proteins (APP) has been shown to generate Abeta peptides (O(2)-).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>In the absence of L-arginine, sequential overlapping fragments (O(2)-) has been generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>In the absence of L-arginine, sequential overlapping fragments (O(2)-) is generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>In the absence of L-arginine, sequential overlapping fragments (O(2)-) was generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>In the absence of L-arginine, sequential overlapping fragments (O(2)-) will be generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>In the absence of L-arginine, specific fragments (O(2)-) has been generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>In the absence of L-arginine, specific fragments (O(2)-) is generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>In the absence of L-arginine, specific fragments (O(2)-) was generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>In the absence of L-arginine, specific fragments (O(2)-) will be generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>In the absence of L-arginine, spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex (O(2)-) has been generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>In the absence of L-arginine, spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex (O(2)-) is generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>In the absence of L-arginine, spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex (O(2)-) was generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>In the absence of L-arginine, spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex (O(2)-) will be generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>In the absence of L-arginine, the 21-23 nt long mature RNAs (O(2)-) has been generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>In the absence of L-arginine, the 21-23 nt long mature RNAs (O(2)-) is generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>In the absence of L-arginine, the 21-23 nt long mature RNAs (O(2)-) was generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>In the absence of L-arginine, the 21-23 nt long mature RNAs (O(2)-) will be generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>In the absence of L-arginine, the correct three-dimensional interaction surface (O(2)-) has been generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>In the absence of L-arginine, the correct three-dimensional interaction surface (O(2)-) is generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>In the absence of L-arginine, the correct three-dimensional interaction surface (O(2)-) was generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>In the absence of L-arginine, the correct three-dimensional interaction surface (O(2)-) will be generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>In the absence of L-arginine, this binding generated a higher order protein-DNA complex (O(2)-).</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>In the absence of L-arginine, this binding generates a higher order protein-DNA complex (O(2)-).</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>In the absence of L-arginine, this binding has been shown to generate a higher order protein-DNA complex (O(2)-).</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>In the absence of L-arginine, us generated a monoclonal antibody against FHL2 (O(2)-).</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>In the absence of L-arginine, us generates a monoclonal antibody against FHL2 (O(2)-).</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>In the absence of L-arginine, us has been shown to generate a monoclonal antibody against FHL2 (O(2)-).</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>In the absence of L-arginine, we generated a monoclonal antibody against FHL2 (O(2)-).</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>In the absence of L-arginine, we generates a monoclonal antibody against FHL2 (O(2)-).</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>In the absence of L-arginine, we has been shown to generate a monoclonal antibody against FHL2 (O(2)-).</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>L723 in H3 can generate the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>L723 in H3 cleaves microRNA precursors to generate the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>L723 in H3 generate the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>L723 in H3 generated the correct three-dimensional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>L723 in H3 generated the correct three-dimensional interaction surface within the recombinational synapse.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>L723 in H3 generated the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>L723 in H3 generates the correct three-dimensional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>L723 in H3 generates the correct three-dimensional interaction surface within the recombinational synapse.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>L723 in H3 generates the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>L723 in H3 has generated the correct three-dimensional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>L723 in H3 has generated the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>L723 in H3 is able to generate the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>L723 in H3 may generate the correct three-dimensional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>L723 in H3 was optimized to generate the correct three-dimensional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>L723 in H3, generating the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>Major transcripts of 1.7 and 2.7 are generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>Major transcripts of 1.7 and 2.7 are generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>Major transcripts of 1.7 and 2.7 are generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>Major transcripts of 1.7 and 2.7 are generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>Major transcripts of 1.7 and 2.7 are generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>Major transcripts of 1.7 and 2.7 are generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>Major transcripts of 1.7 and 2.7 are generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>Major transcripts of 1.7 and 2.7 are generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>Major transcripts of 1.7 and 2.7 are generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>Major transcripts of 1.7 and 2.7 are generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>Major transcripts of 1.7 and 2.7 are generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>Major transcripts of 1.7 and 2.7 are generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>Major transcripts of 1.7 and 2.7 are generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>Major transcripts of 1.7 and 2.7 were generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>Major transcripts of 1.7 and 2.7 were generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>Major transcripts of 1.7 and 2.7 were generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>Major transcripts of 1.7 and 2.7 were generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>Major transcripts of 1.7 and 2.7 were generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>Major transcripts of 1.7 and 2.7 were generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>Major transcripts of 1.7 and 2.7 were generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>Major transcripts of 1.7 and 2.7 were generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>Major transcripts of 1.7 and 2.7 were generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>Major transcripts of 1.7 and 2.7 were generated by proteolysis of the amyloid precursor proteins (APP).</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>Major transcripts of 1.7 and 2.7 were generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>Major transcripts of 1.7 and 2.7 were generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>Major transcripts of 1.7 and 2.7 were generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR can generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR cleaves microRNA precursors to generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR generated spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR generated spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex within the recombinational synapse.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR generates spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR generates spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex within the recombinational synapse.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR generates spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR has generated spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR has generated spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR is able to generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR may generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR was optimized to generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>Prnd cleaves microRNA precursors to generate major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>Prnd generate major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>Prnd generated major transcripts of 1.7 and 2.7 kb ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>Prnd generated major transcripts of 1.7 and 2.7 kb within the recombinational synapse.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>Prnd generates major transcripts of 1.7 and 2.7 kb ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>Prnd generates major transcripts of 1.7 and 2.7 kb within the recombinational synapse.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>Prnd has generated major transcripts of 1.7 and 2.7 kb ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>Prnd has generated major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>Prnd may generate major transcripts of 1.7 and 2.7 kb ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>Prnd was optimized to generate major transcripts of 1.7 and 2.7 kb ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>Prnd, generating major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>Sequential overlapping fragments are generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>Sequential overlapping fragments are generated by L723 in H3 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>Sequential overlapping fragments are generated by NO reacts anaerobically with the Fe-S cluster of purified FNR ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>Sequential overlapping fragments are generated by Prnd ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>Sequential overlapping fragments are generated by The bidentate RNase III Dicer ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>Sequential overlapping fragments are generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>Sequential overlapping fragments are generated by degradation ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>Sequential overlapping fragments are generated by fumarase B ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>Sequential overlapping fragments are generated by nNOS ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>Sequential overlapping fragments are generated by proteolysis of the amyloid precursor proteins (APP) ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>Sequential overlapping fragments are generated by this binding ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>Sequential overlapping fragments are generated by us ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">us</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>Sequential overlapping fragments are generated by we ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">we</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>Sequential overlapping fragments were generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>Sequential overlapping fragments were generated by L723 in H3 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>Sequential overlapping fragments were generated by NO reacts anaerobically with the Fe-S cluster of purified FNR ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>Sequential overlapping fragments were generated by Prnd ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>Sequential overlapping fragments were generated by The bidentate RNase III Dicer ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>Sequential overlapping fragments were generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>Sequential overlapping fragments were generated by degradation ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>Sequential overlapping fragments were generated by fumarase B ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>Sequential overlapping fragments were generated by nNOS ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>Sequential overlapping fragments were generated by proteolysis of the amyloid precursor proteins (APP) ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>Sequential overlapping fragments were generated by this binding ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>Sequential overlapping fragments were generated by us ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">us</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>Sequential overlapping fragments were generated by we ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">we</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>The TBC method can generate sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>The TBC method cleaves microRNA precursors to generate sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>The TBC method generate sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>The TBC method generated sequential overlapping fragments within the recombinational synapse.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>The TBC method generated sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>The TBC method generates sequential overlapping fragments within the recombinational synapse.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>The TBC method generates sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>The TBC method has generated sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>The TBC method is able to generate sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>The TBC method, generating sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>The bidentate RNase III Dicer can generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>The bidentate RNase III Dicer generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>The bidentate RNase III Dicer generated the 21-23 nt long mature RNAs ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>The bidentate RNase III Dicer generated the 21-23 nt long mature RNAs within the recombinational synapse.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>The bidentate RNase III Dicer generates the 21-23 nt long mature RNAs ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>The bidentate RNase III Dicer generates the 21-23 nt long mature RNAs within the recombinational synapse.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>The bidentate RNase III Dicer has generated the 21-23 nt long mature RNAs ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>The bidentate RNase III Dicer may generate the 21-23 nt long mature RNAs ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>The bidentate RNase III Dicer was optimized to generate the 21-23 nt long mature RNAs ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>The bidentate RNase III Dicer, generating the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>These are Abeta peptides reductase (encoded by the frdABCD operon), proteolysis of the amyloid precursor proteins (APP), which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>These are Abeta peptides reductase (encoded by the frdABCD operon), proteolysis of the amyloid precursor proteins (APP), which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>These are Abeta peptides reductase (encoded by the frdABCD operon), proteolysis of the amyloid precursor proteins (APP), which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>These are Abeta peptides reductase (encoded by the frdABCD operon), proteolysis of the amyloid precursor proteins (APP), which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>These are a DNase I hypersensitive reductase (encoded by the frdABCD operon), a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>These are a DNase I hypersensitive reductase (encoded by the frdABCD operon), a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>These are a DNase I hypersensitive reductase (encoded by the frdABCD operon), a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>These are a DNase I hypersensitive reductase (encoded by the frdABCD operon), a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>These are a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro reductase (encoded by the frdABCD operon), EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>These are a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro reductase (encoded by the frdABCD operon), EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>These are a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro reductase (encoded by the frdABCD operon), EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>These are a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro reductase (encoded by the frdABCD operon), EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>These are a higher order protein-DNA complex reductase (encoded by the frdABCD operon), this binding, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>These are a higher order protein-DNA complex reductase (encoded by the frdABCD operon), this binding, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>These are a higher order protein-DNA complex reductase (encoded by the frdABCD operon), this binding, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>These are a higher order protein-DNA complex reductase (encoded by the frdABCD operon), this binding, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>These are a monoclonal antibody against FHL2 reductase (encoded by the frdABCD operon), us, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>These are a monoclonal antibody against FHL2 reductase (encoded by the frdABCD operon), us, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>These are a monoclonal antibody against FHL2 reductase (encoded by the frdABCD operon), us, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>These are a monoclonal antibody against FHL2 reductase (encoded by the frdABCD operon), us, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>These are a monoclonal antibody against FHL2 reductase (encoded by the frdABCD operon), we, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>These are a monoclonal antibody against FHL2 reductase (encoded by the frdABCD operon), we, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>These are a monoclonal antibody against FHL2 reductase (encoded by the frdABCD operon), we, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>These are a monoclonal antibody against FHL2 reductase (encoded by the frdABCD operon), we, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>These are major transcripts of 1.7 and 2.7 kb reductase (encoded by the frdABCD operon), Prnd, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>These are major transcripts of 1.7 and 2.7 kb reductase (encoded by the frdABCD operon), Prnd, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>These are major transcripts of 1.7 and 2.7 kb reductase (encoded by the frdABCD operon), Prnd, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>These are major transcripts of 1.7 and 2.7 kb reductase (encoded by the frdABCD operon), Prnd, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>These are sequential overlapping fragments reductase (encoded by the frdABCD operon), The TBC method, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>These are sequential overlapping fragments reductase (encoded by the frdABCD operon), The TBC method, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>These are sequential overlapping fragments reductase (encoded by the frdABCD operon), The TBC method, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>These are sequential overlapping fragments reductase (encoded by the frdABCD operon), The TBC method, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>These are specific fragments reductase (encoded by the frdABCD operon), degradation, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>These are specific fragments reductase (encoded by the frdABCD operon), degradation, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>These are specific fragments reductase (encoded by the frdABCD operon), degradation, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>These are specific fragments reductase (encoded by the frdABCD operon), degradation, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>These are spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex reductase (encoded by the frdABCD operon), NO reacts anaerobically with the Fe-S cluster of purified FNR, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>These are spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex reductase (encoded by the frdABCD operon), NO reacts anaerobically with the Fe-S cluster of purified FNR, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>These are spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex reductase (encoded by the frdABCD operon), NO reacts anaerobically with the Fe-S cluster of purified FNR, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>These are spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex reductase (encoded by the frdABCD operon), NO reacts anaerobically with the Fe-S cluster of purified FNR, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>These are superoxide reductase (encoded by the frdABCD operon), nNOS, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>These are superoxide reductase (encoded by the frdABCD operon), nNOS, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>These are superoxide reductase (encoded by the frdABCD operon), nNOS, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>These are superoxide reductase (encoded by the frdABCD operon), nNOS, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>These are the 21-23 nt long mature RNAs reductase (encoded by the frdABCD operon), The bidentate RNase III Dicer, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>These are the 21-23 nt long mature RNAs reductase (encoded by the frdABCD operon), The bidentate RNase III Dicer, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>These are the 21-23 nt long mature RNAs reductase (encoded by the frdABCD operon), The bidentate RNase III Dicer, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>These are the 21-23 nt long mature RNAs reductase (encoded by the frdABCD operon), The bidentate RNase III Dicer, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>These are the correct three-dimensional interaction surface reductase (encoded by the frdABCD operon), L723 in H3, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>These are the correct three-dimensional interaction surface reductase (encoded by the frdABCD operon), L723 in H3, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>These are the correct three-dimensional interaction surface reductase (encoded by the frdABCD operon), L723 in H3, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>These are the correct three-dimensional interaction surface reductase (encoded by the frdABCD operon), L723 in H3, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>To analyse specifically protein expression of FHL2 in human tissues EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>To analyse specifically protein expression of FHL2 in human tissues EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) may generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>To analyse specifically protein expression of FHL2 in human tissues L723 in H3 generated the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>To analyse specifically protein expression of FHL2 in human tissues L723 in H3 may generate the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>To analyse specifically protein expression of FHL2 in human tissues NO reacts anaerobically with the Fe-S cluster of purified FNR generated spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>To analyse specifically protein expression of FHL2 in human tissues NO reacts anaerobically with the Fe-S cluster of purified FNR may generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>To analyse specifically protein expression of FHL2 in human tissues Prnd generated major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>To analyse specifically protein expression of FHL2 in human tissues Prnd may generate major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>To analyse specifically protein expression of FHL2 in human tissues The TBC method generated sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>To analyse specifically protein expression of FHL2 in human tissues The TBC method may generate sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>To analyse specifically protein expression of FHL2 in human tissues The bidentate RNase III Dicer generated the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>To analyse specifically protein expression of FHL2 in human tissues The bidentate RNase III Dicer may generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>To analyse specifically protein expression of FHL2 in human tissues a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>To analyse specifically protein expression of FHL2 in human tissues a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) may generate a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>To analyse specifically protein expression of FHL2 in human tissues degradation generated specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>To analyse specifically protein expression of FHL2 in human tissues degradation may generate specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>To analyse specifically protein expression of FHL2 in human tissues fumarase B generated fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>To analyse specifically protein expression of FHL2 in human tissues fumarase B may generate fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>To analyse specifically protein expression of FHL2 in human tissues nNOS generated superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>To analyse specifically protein expression of FHL2 in human tissues nNOS may generate superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>To analyse specifically protein expression of FHL2 in human tissues proteolysis of the amyloid precursor proteins (APP) generated Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>To analyse specifically protein expression of FHL2 in human tissues proteolysis of the amyloid precursor proteins (APP) may generate Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>To analyse specifically protein expression of FHL2 in human tissues this binding generated a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>To analyse specifically protein expression of FHL2 in human tissues this binding may generate a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>To analyse specifically protein expression of FHL2 in human tissues us generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>To analyse specifically protein expression of FHL2 in human tissues us may generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, Abeta peptides is generated by proteolysis of the amyloid precursor proteins (APP)</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, Abeta peptides was generated by proteolysis of the amyloid precursor proteins (APP)</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) will generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, L723 in H3 generate the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, L723 in H3 will generate the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, NO reacts anaerobically with the Fe-S cluster of purified FNR generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, NO reacts anaerobically with the Fe-S cluster of purified FNR will generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, Prnd generate major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, Prnd will generate major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, The TBC method generate sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, The TBC method will generate sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, The bidentate RNase III Dicer generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, The bidentate RNase III Dicer will generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a DNase I hypersensitive is generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a DNase I hypersensitive was generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro is generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro was generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generate a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) will generate a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a higher order protein-DNA complex is generated by this binding</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a higher order protein-DNA complex was generated by this binding</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a monoclonal antibody against FHL2 is generated by we</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a monoclonal antibody against FHL2 was generated by we</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, degradation generate specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, degradation will generate specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, fumarase B generate fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, fumarase B will generate fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, fumarate is generated by fumarase B</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, fumarate was generated by fumarase B</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, major transcripts of 1.7 and 2.7 kb is generated by Prnd</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, major transcripts of 1.7 and 2.7 kb was generated by Prnd</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, nNOS generate superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, nNOS will generate superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, proteolysis of the amyloid precursor proteins (APP) generate Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, proteolysis of the amyloid precursor proteins (APP) will generate Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, sequential overlapping fragments is generated by The TBC method</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, sequential overlapping fragments was generated by The TBC method</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, specific fragments is generated by degradation</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, specific fragments was generated by degradation</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex is generated by NO reacts anaerobically with the Fe-S cluster of purified FNR</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex was generated by NO reacts anaerobically with the Fe-S cluster of purified FNR</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, superoxide is generated by nNOS</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, superoxide was generated by nNOS</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, the 21-23 nt long mature RNAs is generated by The bidentate RNase III Dicer</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, the 21-23 nt long mature RNAs was generated by The bidentate RNase III Dicer</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, the correct three-dimensional interaction surface is generated by L723 in H3</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, the correct three-dimensional interaction surface was generated by L723 in H3</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, this binding generate a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, this binding will generate a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, us generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, us will generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>We believe EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is found to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro within the recombinational synapse.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>We believe EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is required to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro within the recombinational synapse.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>We believe EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is shown to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro within the recombinational synapse.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>We believe L723 in H3 is found to generate the correct three-dimensional interaction surface within the recombinational synapse.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>We believe L723 in H3 is required to generate the correct three-dimensional interaction surface within the recombinational synapse.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>We believe L723 in H3 is shown to generate the correct three-dimensional interaction surface within the recombinational synapse.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>We believe NO reacts anaerobically with the Fe-S cluster of purified FNR is found to generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex within the recombinational synapse.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>We believe NO reacts anaerobically with the Fe-S cluster of purified FNR is required to generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex within the recombinational synapse.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>We believe NO reacts anaerobically with the Fe-S cluster of purified FNR is shown to generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex within the recombinational synapse.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>We believe Prnd is found to generate major transcripts of 1.7 and 2.7 kb within the recombinational synapse.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>We believe Prnd is required to generate major transcripts of 1.7 and 2.7 kb within the recombinational synapse.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>We believe Prnd is shown to generate major transcripts of 1.7 and 2.7 kb within the recombinational synapse.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>We believe The TBC method is found to generate sequential overlapping fragments within the recombinational synapse.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>We believe The TBC method is required to generate sequential overlapping fragments within the recombinational synapse.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>We believe The TBC method is shown to generate sequential overlapping fragments within the recombinational synapse.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>We believe The bidentate RNase III Dicer is found to generate the 21-23 nt long mature RNAs within the recombinational synapse.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>We believe The bidentate RNase III Dicer is required to generate the 21-23 nt long mature RNAs within the recombinational synapse.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>We believe The bidentate RNase III Dicer is shown to generate the 21-23 nt long mature RNAs within the recombinational synapse.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>We believe a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is found to generate a DNase I hypersensitive within the recombinational synapse.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>We believe a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is required to generate a DNase I hypersensitive within the recombinational synapse.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>We believe a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is shown to generate a DNase I hypersensitive within the recombinational synapse.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>We believe degradation is found to generate specific fragments within the recombinational synapse.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>We believe degradation is required to generate specific fragments within the recombinational synapse.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>We believe degradation is shown to generate specific fragments within the recombinational synapse.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>We believe fumarase B is found to generate fumarate within the recombinational synapse.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>We believe fumarase B is required to generate fumarate within the recombinational synapse.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>We believe fumarase B is shown to generate fumarate within the recombinational synapse.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>We believe nNOS is found to generate superoxide within the recombinational synapse.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>We believe nNOS is required to generate superoxide within the recombinational synapse.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>We believe nNOS is shown to generate superoxide within the recombinational synapse.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>We believe proteolysis of the amyloid precursor proteins (APP) is found to generate Abeta peptides within the recombinational synapse.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>We believe proteolysis of the amyloid precursor proteins (APP) is required to generate Abeta peptides within the recombinational synapse.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>We believe proteolysis of the amyloid precursor proteins (APP) is shown to generate Abeta peptides within the recombinational synapse.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>We believe us is found to generate a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>We believe us is required to generate a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>We believe us is shown to generate a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>We believe we is found to generate a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>We believe we is required to generate a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>We believe we is shown to generate a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>We show that L723 in H3, to generate the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>We show that NO reacts anaerobically with the Fe-S cluster of purified FNR, to generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>We show that Prnd, to generate major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>We show that The TBC method, to generate sequential overlapping fragments.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>We show that The bidentate RNase III Dicer, to generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>We show that a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), to generate a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>We show that degradation, to generate specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>We show that fumarase B, to generate fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>We show that nNOS, to generate superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>We show that proteolysis of the amyloid precursor proteins (APP), to generate Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>We show that this binding, to generate a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>We show that us, to generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>We show that we, to generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>a DNase I hypersensitive (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>a DNase I hypersensitive (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>a DNase I hypersensitive are generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>a DNase I hypersensitive are generated from a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) by beta- and gamma-secretases.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>a DNase I hypersensitive can be generated from a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) by beta- and gamma-secretases.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>a DNase I hypersensitive have been generated from a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) by beta- and gamma-secretases.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>a DNase I hypersensitive is generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) within the recombinational synapse.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>a DNase I hypersensitive was generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) within the recombinational synapse.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>a DNase I hypersensitive were generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>a DNase I hypersensitive were generated from a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) by beta- and gamma-secretases.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro are generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro are generated from EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) by beta- and gamma-secretases.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro can be generated from EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) by beta- and gamma-secretases.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro have been generated from EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) by beta- and gamma-secretases.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro is generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) within the recombinational synapse.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro is generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro was generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) within the recombinational synapse.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro was generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro were generated by EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro were generated from EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) by beta- and gamma-secretases.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) can generate a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) cleaves microRNA precursors to generate a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive within the recombinational synapse.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive within the recombinational synapse.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generates a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) has generated a DNase I hypersensitive ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) has generated a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) is able to generate a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) may generate a DNase I hypersensitive ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) was optimized to generate a DNase I hypersensitive ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), generating a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>a higher order protein-DNA complex (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>a higher order protein-DNA complex (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>a higher order protein-DNA complex are generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>a higher order protein-DNA complex are generated from this binding by beta- and gamma-secretases.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>a higher order protein-DNA complex can be generated from this binding by beta- and gamma-secretases.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>a higher order protein-DNA complex have been generated from this binding by beta- and gamma-secretases.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>a higher order protein-DNA complex is generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>a higher order protein-DNA complex was generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>a higher order protein-DNA complex were generated by this binding.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>a higher order protein-DNA complex were generated from this binding by beta- and gamma-secretases.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>a monoclonal antibody against FHL2 (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>a monoclonal antibody against FHL2 (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>a monoclonal antibody against FHL2 (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>a monoclonal antibody against FHL2 (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>a monoclonal antibody against FHL2 are generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>a monoclonal antibody against FHL2 are generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>a monoclonal antibody against FHL2 are generated from us by beta- and gamma-secretases.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>a monoclonal antibody against FHL2 are generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>a monoclonal antibody against FHL2 can be generated from us by beta- and gamma-secretases.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>a monoclonal antibody against FHL2 can be generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>a monoclonal antibody against FHL2 have been generated from us by beta- and gamma-secretases.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>a monoclonal antibody against FHL2 have been generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>a monoclonal antibody against FHL2 is generated by us within the recombinational synapse.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>a monoclonal antibody against FHL2 is generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>a monoclonal antibody against FHL2 is generated by we within the recombinational synapse.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>a monoclonal antibody against FHL2 is generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>a monoclonal antibody against FHL2 was generated by us within the recombinational synapse.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>a monoclonal antibody against FHL2 was generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>a monoclonal antibody against FHL2 was generated by we within the recombinational synapse.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>a monoclonal antibody against FHL2 was generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>a monoclonal antibody against FHL2 were generated by us.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>a monoclonal antibody against FHL2 were generated by we.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>a monoclonal antibody against FHL2 were generated from us by beta- and gamma-secretases.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>a monoclonal antibody against FHL2 were generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>degradation can generate specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>degradation cleaves microRNA precursors to generate specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>degradation generate specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>degradation generated specific fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>degradation generated specific fragments within the recombinational synapse.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>degradation generated specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>degradation generates specific fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>degradation generates specific fragments within the recombinational synapse.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>degradation generates specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>degradation has generated specific fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>degradation has generated specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>degradation is able to generate specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>degradation may generate specific fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>degradation was optimized to generate specific fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>degradation, generating specific fragments.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>fumarase B can generate fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>fumarase B cleaves microRNA precursors to generate fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>fumarase B generate fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>fumarase B generated fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>fumarase B generated fumarate within the recombinational synapse.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>fumarase B generated fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>fumarase B generates fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>fumarase B generates fumarate within the recombinational synapse.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>fumarase B generates fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>fumarase B has generated fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>fumarase B has generated fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>fumarase B is able to generate fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>fumarase B may generate fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>fumarase B was optimized to generate fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>fumarase B, generating fumarate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>fumarate are generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>fumarate are generated from fumarase B by beta- and gamma-secretases.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>fumarate can be generated from fumarase B by beta- and gamma-secretases.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>fumarate have been generated from fumarase B by beta- and gamma-secretases.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>fumarate is generated by fumarase B within the recombinational synapse.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>fumarate is generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>fumarate was generated by fumarase B within the recombinational synapse.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>fumarate was generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>fumarate were generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>fumarate were generated from fumarase B by beta- and gamma-secretases.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>major transcripts of 1.7 and 2.7 kb (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>major transcripts of 1.7 and 2.7 kb (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>major transcripts of 1.7 and 2.7 kb are generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>major transcripts of 1.7 and 2.7 kb are generated from Prnd by beta- and gamma-secretases.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>major transcripts of 1.7 and 2.7 kb can be generated from Prnd by beta- and gamma-secretases.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>major transcripts of 1.7 and 2.7 kb have been generated from Prnd by beta- and gamma-secretases.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>major transcripts of 1.7 and 2.7 kb is generated by Prnd within the recombinational synapse.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>major transcripts of 1.7 and 2.7 kb is generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>major transcripts of 1.7 and 2.7 kb was generated by Prnd within the recombinational synapse.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>major transcripts of 1.7 and 2.7 kb was generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>major transcripts of 1.7 and 2.7 kb were generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>major transcripts of 1.7 and 2.7 kb were generated from Prnd by beta- and gamma-secretases.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>nNOS can generate superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>nNOS cleaves microRNA precursors to generate superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>nNOS generate superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>nNOS generated superoxide ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>nNOS generated superoxide within the recombinational synapse.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>nNOS generated superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>nNOS generates superoxide ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>nNOS generates superoxide within the recombinational synapse.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>nNOS generates superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>nNOS has generated superoxide ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>nNOS has generated superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>nNOS is able to generate superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>nNOS may generate superoxide ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>nNOS was optimized to generate superoxide ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>nNOS, generating superoxide.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>proteolysis of the amyloid precursor proteins (APP) can generate Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>proteolysis of the amyloid precursor proteins (APP) cleaves microRNA precursors to generate Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>proteolysis of the amyloid precursor proteins (APP) generate Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>proteolysis of the amyloid precursor proteins (APP) generated Abeta peptides ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>proteolysis of the amyloid precursor proteins (APP) generated Abeta peptides within the recombinational synapse.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>proteolysis of the amyloid precursor proteins (APP) generated Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>proteolysis of the amyloid precursor proteins (APP) generates Abeta peptides ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>proteolysis of the amyloid precursor proteins (APP) generates Abeta peptides within the recombinational synapse.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>proteolysis of the amyloid precursor proteins (APP) generates Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>proteolysis of the amyloid precursor proteins (APP) has generated Abeta peptides ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>proteolysis of the amyloid precursor proteins (APP) has generated Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>proteolysis of the amyloid precursor proteins (APP) is able to generate Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>proteolysis of the amyloid precursor proteins (APP) may generate Abeta peptides ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>proteolysis of the amyloid precursor proteins (APP) was optimized to generate Abeta peptides ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>proteolysis of the amyloid precursor proteins (APP), generating Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>proteolysis of the amyloid precursor proteins generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>proteolysis of the amyloid precursor proteins generate a DNase I hypersensitive.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>proteolysis of the amyloid precursor proteins generate a higher order protein-DNA complex.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>proteolysis of the amyloid precursor proteins generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>proteolysis of the amyloid precursor proteins generate fumarate.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>proteolysis of the amyloid precursor proteins generate major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>proteolysis of the amyloid precursor proteins generate sequential overlapping fragments.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>proteolysis of the amyloid precursor proteins generate specific fragments.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>proteolysis of the amyloid precursor proteins generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>proteolysis of the amyloid precursor proteins generate superoxide.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>proteolysis of the amyloid precursor proteins generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>proteolysis of the amyloid precursor proteins generate the correct three-dimensional interaction surface.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>proteolysis of the amyloid precursor proteins generated a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>proteolysis of the amyloid precursor proteins generated a DNase I hypersensitive.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>proteolysis of the amyloid precursor proteins generated a higher order protein-DNA complex.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>proteolysis of the amyloid precursor proteins generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>proteolysis of the amyloid precursor proteins generated fumarate.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>proteolysis of the amyloid precursor proteins generated major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>proteolysis of the amyloid precursor proteins generated sequential overlapping fragments.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>proteolysis of the amyloid precursor proteins generated specific fragments.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>proteolysis of the amyloid precursor proteins generated spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>proteolysis of the amyloid precursor proteins generated superoxide.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>proteolysis of the amyloid precursor proteins generated the 21-23 nt long mature RNAs.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>proteolysis of the amyloid precursor proteins generated the correct three-dimensional interaction surface.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>sequential overlapping fragments (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>sequential overlapping fragments (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>sequential overlapping fragments are generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>sequential overlapping fragments are generated from The TBC method by beta- and gamma-secretases.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>sequential overlapping fragments can be generated from The TBC method by beta- and gamma-secretases.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>sequential overlapping fragments have been generated from The TBC method by beta- and gamma-secretases.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>sequential overlapping fragments is generated by The TBC method within the recombinational synapse.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>sequential overlapping fragments is generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>sequential overlapping fragments was generated by The TBC method within the recombinational synapse.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>sequential overlapping fragments was generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>sequential overlapping fragments were generated by The TBC method.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>sequential overlapping fragments were generated from The TBC method by beta- and gamma-secretases.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>specific fragments (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>specific fragments (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>specific fragments are generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>specific fragments are generated from degradation by beta- and gamma-secretases.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>specific fragments can be generated from degradation by beta- and gamma-secretases.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>specific fragments have been generated from degradation by beta- and gamma-secretases.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>specific fragments is generated by degradation within the recombinational synapse.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>specific fragments is generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>specific fragments was generated by degradation within the recombinational synapse.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>specific fragments was generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>specific fragments were generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>specific fragments were generated from degradation by beta- and gamma-secretases.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex are generated from NO reacts anaerobically with the Fe-S cluster of purified FNR by beta- and gamma-secretases.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex can be generated from NO reacts anaerobically with the Fe-S cluster of purified FNR by beta- and gamma-secretases.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex have been generated from NO reacts anaerobically with the Fe-S cluster of purified FNR by beta- and gamma-secretases.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex is generated by NO reacts anaerobically with the Fe-S cluster of purified FNR within the recombinational synapse.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex is generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex was generated by NO reacts anaerobically with the Fe-S cluster of purified FNR within the recombinational synapse.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex was generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex were generated from NO reacts anaerobically with the Fe-S cluster of purified FNR by beta- and gamma-secretases.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>superoxide (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>superoxide (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>superoxide are generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>superoxide are generated from nNOS by beta- and gamma-secretases.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>superoxide can be generated from nNOS by beta- and gamma-secretases.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>superoxide have been generated from nNOS by beta- and gamma-secretases.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>superoxide is generated by nNOS within the recombinational synapse.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>superoxide is generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>superoxide was generated by nNOS within the recombinational synapse.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>superoxide was generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>superoxide were generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>superoxide were generated from nNOS by beta- and gamma-secretases.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>the 21-23 nt long mature RNAs (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>the 21-23 nt long mature RNAs (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="799">
                    <text>the 21-23 nt long mature RNAs are generated from The bidentate RNase III Dicer by beta- and gamma-secretases.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="800">
                    <text>the 21-23 nt long mature RNAs can be generated from The bidentate RNase III Dicer by beta- and gamma-secretases.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="801">
                    <text>the 21-23 nt long mature RNAs have been generated from The bidentate RNase III Dicer by beta- and gamma-secretases.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="802">
                    <text>the 21-23 nt long mature RNAs is generated by The bidentate RNase III Dicer within the recombinational synapse.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="803">
                    <text>the 21-23 nt long mature RNAs is generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="804">
                    <text>the 21-23 nt long mature RNAs was generated by The bidentate RNase III Dicer within the recombinational synapse.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="805">
                    <text>the 21-23 nt long mature RNAs was generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="806">
                    <text>the 21-23 nt long mature RNAs were generated from The bidentate RNase III Dicer by beta- and gamma-secretases.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="PERMUTATE" no="807">
                    <text>the correct three-dimensional interaction surface (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="808">
                    <text>the correct three-dimensional interaction surface (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="809">
                    <text>the correct three-dimensional interaction surface are generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="810">
                    <text>the correct three-dimensional interaction surface are generated from L723 in H3 by beta- and gamma-secretases.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="811">
                    <text>the correct three-dimensional interaction surface can be generated from L723 in H3 by beta- and gamma-secretases.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="812">
                    <text>the correct three-dimensional interaction surface have been generated from L723 in H3 by beta- and gamma-secretases.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="813">
                    <text>the correct three-dimensional interaction surface is generated by L723 in H3 within the recombinational synapse.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="814">
                    <text>the correct three-dimensional interaction surface is generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="815">
                    <text>the correct three-dimensional interaction surface was generated by L723 in H3 within the recombinational synapse.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="816">
                    <text>the correct three-dimensional interaction surface was generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="817">
                    <text>the correct three-dimensional interaction surface were generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="818">
                    <text>the correct three-dimensional interaction surface were generated from L723 in H3 by beta- and gamma-secretases.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="PERMUTATE" no="819">
                    <text>this binding can generate a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="820">
                    <text>this binding cleaves microRNA precursors to generate a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="821">
                    <text>this binding generate a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="822">
                    <text>this binding generated a higher order protein-DNA complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="823">
                    <text>this binding generated a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="824">
                    <text>this binding generates a higher order protein-DNA complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="825">
                    <text>this binding generates a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="826">
                    <text>this binding has generated a higher order protein-DNA complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="827">
                    <text>this binding has generated a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="828">
                    <text>this binding is able to generate a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="829">
                    <text>this binding may generate a higher order protein-DNA complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="830">
                    <text>this binding was optimized to generate a higher order protein-DNA complex ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="831">
                    <text>this binding, generating a higher order protein-DNA complex.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="PERMUTATE" no="832">
                    <text>us can generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="833">
                    <text>us cleaves microRNA precursors to generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="834">
                    <text>us generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="835">
                    <text>us generated a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="836">
                    <text>us generated a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="837">
                    <text>us generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="838">
                    <text>us generates a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="839">
                    <text>us generates a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="840">
                    <text>us generates a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="841">
                    <text>us has generated a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="842">
                    <text>us has generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="843">
                    <text>us is able to generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="844">
                    <text>us may generate a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="845">
                    <text>us was optimized to generate a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="846">
                    <text>us, generating a monoclonal antibody against FHL2.</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="847">
                    <text>we can generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="848">
                    <text>we cleaves microRNA precursors to generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="849">
                    <text>we generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="850">
                    <text>we generated a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="851">
                    <text>we generated a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="852">
                    <text>we generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="853">
                    <text>we generates a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="854">
                    <text>we generates a monoclonal antibody against FHL2 within the recombinational synapse.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="855">
                    <text>we generates a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="856">
                    <text>we has generated a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="857">
                    <text>we has generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="858">
                    <text>we is able to generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="859">
                    <text>we may generate a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="860">
                    <text>we was optimized to generate a monoclonal antibody against FHL2 ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="PERMUTATE" no="861">
                    <text>we, generating a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Human leukocyte antigen (HLA)-G molecules has been generated by an alternative splicing of the primary transcript of the gene</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Human leukocyte antigen (HLA)-G molecules is generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Human leukocyte antigen (HLA)-G molecules was generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that Human leukocyte antigen (HLA)-G molecules will be generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The DNA-binding mutant (Stat5aEE-AA) of Stat5a has been generated by mutating amino acids EE (437 and 438) to AA</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The DNA-binding mutant (Stat5aEE-AA) of Stat5a is generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The DNA-binding mutant (Stat5aEE-AA) of Stat5a was generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that The DNA-binding mutant (Stat5aEE-AA) of Stat5a will be generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a functional interaction surface has been generated by the AR N-terminus</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a functional interaction surface is generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a functional interaction surface was generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that a functional interaction surface will be generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that an RNA splice of 3863 bases occurs in the 5-untranslated region generated mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that an RNA splice of 3863 bases occurs in the 5-untranslated region generates mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that an RNA splice of 3863 bases occurs in the 5-untranslated region is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that an alternative splicing of the primary transcript of the gene generated Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that an alternative splicing of the primary transcript of the gene generates Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that an alternative splicing of the primary transcript of the gene is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that aspartate-ammonia lyase generated fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that aspartate-ammonia lyase generates fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that aspartate-ammonia lyase is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarate has been generated by aspartate-ammonia lyase</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarate is generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarate was generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that fumarate will be generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that intergenic splicing with Prnp generated some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that intergenic splicing with Prnp generates some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that intergenic splicing with Prnp is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that mature HeLa cell mRNA has been generated by an RNA splice of 3863 bases occurs in the 5-untranslated region</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that mature HeLa cell mRNA is generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that mature HeLa cell mRNA was generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that mature HeLa cell mRNA will be generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that mutating amino acids EE (437 and 438) to AA generated The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that mutating amino acids EE (437 and 438) to AA generates The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that mutating amino acids EE (437 and 438) to AA is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that some unusual chimeric transcripts has been generated by intergenic splicing with Prnp</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that some unusual chimeric transcripts is generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that some unusual chimeric transcripts was generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that some unusual chimeric transcripts will be generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the AR N-terminus generated a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the AR N-terminus generates a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the AR N-terminus is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>Human leukocyte antigen (HLA)-G molecules (from malate, and the DcuB permease for fumarate, malate, and aspartate) an alternative splicing of the primary transcript of the genere generated by we.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>Human leukocyte antigen (HLA)-G molecules (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>Human leukocyte antigen (HLA)-G molecules (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>Human leukocyte antigen (HLA)-G molecules an alternative splicing of the primary transcript of the genere generated by we.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>Human leukocyte antigen (HLA)-G molecules an alternative splicing of the primary transcript of the genere generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>Human leukocyte antigen (HLA)-G molecules are generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>Human leukocyte antigen (HLA)-G molecules are generated from an alternative splicing of the primary transcript of the gene by beta- and gamma-secretases.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>Human leukocyte antigen (HLA)-G molecules can be generated from an alternative splicing of the primary transcript of the gene by beta- and gamma-secretases.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>Human leukocyte antigen (HLA)-G molecules have been generated from an alternative splicing of the primary transcript of the gene by beta- and gamma-secretases.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>Human leukocyte antigen (HLA)-G molecules is generated by an alternative splicing of the primary transcript of the gene within the recombinational synapse.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>Human leukocyte antigen (HLA)-G molecules is generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>Human leukocyte antigen (HLA)-G molecules was generated by an alternative splicing of the primary transcript of the gene within the recombinational synapse.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>Human leukocyte antigen (HLA)-G molecules was generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>Human leukocyte antigen (HLA)-G molecules were generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>Human leukocyte antigen (HLA)-G molecules were generated from an alternative splicing of the primary transcript of the gene by beta- and gamma-secretases.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>In addition, there was an apparent absence of loPrndr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation did not generate major transcripts of 1.7 and 2.7 kb or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>In addition, there was an apparent absence of loPrndr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation does not generate major transcripts of 1.7 and 2.7 kb or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>In addition, there was an apparent absence of loPrndr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that major transcripts of 1.7 and 2.7 kb are not generated by degradation.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>In addition, there was an apparent absence of loPrndr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that major transcripts of 1.7 and 2.7 kb have not been generated by degradation.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>In addition, there was an apparent absence of loPrndr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that major transcripts of 1.7 and 2.7 kb were not generated by degradation.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>In addition, there was an apparent absence of loPrndr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that major transcripts of 1.7 and 2.7 kb will not be generated by degradation.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>In addition, there was an apparent absence of loan RNA splice of 3863 bases occurs in the 5-untranslated regionr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation did not generate mature HeLa cell mRNA or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>In addition, there was an apparent absence of loan RNA splice of 3863 bases occurs in the 5-untranslated regionr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation does not generate mature HeLa cell mRNA or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>In addition, there was an apparent absence of loan RNA splice of 3863 bases occurs in the 5-untranslated regionr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that mature HeLa cell mRNA are not generated by degradation.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>In addition, there was an apparent absence of loan RNA splice of 3863 bases occurs in the 5-untranslated regionr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that mature HeLa cell mRNA have not been generated by degradation.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>In addition, there was an apparent absence of loan RNA splice of 3863 bases occurs in the 5-untranslated regionr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that mature HeLa cell mRNA were not generated by degradation.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>In addition, there was an apparent absence of loan RNA splice of 3863 bases occurs in the 5-untranslated regionr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that mature HeLa cell mRNA will not be generated by degradation.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>In addition, there was an apparent absence of loan alternative splicing of the primary transcript of the gener molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that Human leukocyte antigen (HLA)-G molecules are not generated by degradation.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>In addition, there was an apparent absence of loan alternative splicing of the primary transcript of the gener molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that Human leukocyte antigen (HLA)-G molecules have not been generated by degradation.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>In addition, there was an apparent absence of loan alternative splicing of the primary transcript of the gener molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that Human leukocyte antigen (HLA)-G molecules were not generated by degradation.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>In addition, there was an apparent absence of loan alternative splicing of the primary transcript of the gener molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that Human leukocyte antigen (HLA)-G molecules will not be generated by degradation.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>In addition, there was an apparent absence of loan alternative splicing of the primary transcript of the gener molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation did not generate Human leukocyte antigen (HLA)-G molecules or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>In addition, there was an apparent absence of loan alternative splicing of the primary transcript of the gener molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation does not generate Human leukocyte antigen (HLA)-G molecules or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>In addition, there was an apparent absence of loaspartate-ammonia lyaser molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation did not generate fumarate or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>In addition, there was an apparent absence of loaspartate-ammonia lyaser molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation does not generate fumarate or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>In addition, there was an apparent absence of loaspartate-ammonia lyaser molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that fumarate are not generated by degradation.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>In addition, there was an apparent absence of loaspartate-ammonia lyaser molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that fumarate have not been generated by degradation.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>In addition, there was an apparent absence of loaspartate-ammonia lyaser molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that fumarate were not generated by degradation.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>In addition, there was an apparent absence of loaspartate-ammonia lyaser molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that fumarate will not be generated by degradation.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>In addition, there was an apparent absence of lointergenic splicing with Prnpr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation did not generate some unusual chimeric transcripts or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>In addition, there was an apparent absence of lointergenic splicing with Prnpr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation does not generate some unusual chimeric transcripts or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>In addition, there was an apparent absence of lointergenic splicing with Prnpr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that some unusual chimeric transcripts are not generated by degradation.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>In addition, there was an apparent absence of lointergenic splicing with Prnpr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that some unusual chimeric transcripts have not been generated by degradation.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>In addition, there was an apparent absence of lointergenic splicing with Prnpr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that some unusual chimeric transcripts were not generated by degradation.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>In addition, there was an apparent absence of lointergenic splicing with Prnpr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that some unusual chimeric transcripts will not be generated by degradation.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>In addition, there was an apparent absence of lomutating amino acids EE (437 and 438) to AAr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that The DNA-binding mutant (Stat5aEE-AA) of Stat5a are not generated by degradation.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>In addition, there was an apparent absence of lomutating amino acids EE (437 and 438) to AAr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that The DNA-binding mutant (Stat5aEE-AA) of Stat5a have not been generated by degradation.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>In addition, there was an apparent absence of lomutating amino acids EE (437 and 438) to AAr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that The DNA-binding mutant (Stat5aEE-AA) of Stat5a were not generated by degradation.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>In addition, there was an apparent absence of lomutating amino acids EE (437 and 438) to AAr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that The DNA-binding mutant (Stat5aEE-AA) of Stat5a will not be generated by degradation.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>In addition, there was an apparent absence of lomutating amino acids EE (437 and 438) to AAr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation did not generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>In addition, there was an apparent absence of lomutating amino acids EE (437 and 438) to AAr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation does not generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>In addition, there was an apparent absence of lothe AR N-terminusr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that a functional interaction surface are not generated by degradation.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>In addition, there was an apparent absence of lothe AR N-terminusr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that a functional interaction surface have not been generated by degradation.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>In addition, there was an apparent absence of lothe AR N-terminusr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that a functional interaction surface were not generated by degradation.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>In addition, there was an apparent absence of lothe AR N-terminusr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that a functional interaction surface will not be generated by degradation.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>In addition, there was an apparent absence of lothe AR N-terminusr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation did not generate a functional interaction surface or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>In addition, there was an apparent absence of lothe AR N-terminusr molecular weight fragments as evidence of we, although again the relatively small fraction involved and the possibility that degradation does not generate a functional interaction surface or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an RNA splice of 3863 bases occurs in the 5-untranslated region, although again the relatively small fraction involved and the possibility that degradation did not generate mature HeLa cell mRNA or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an RNA splice of 3863 bases occurs in the 5-untranslated region, although again the relatively small fraction involved and the possibility that degradation does not generate mature HeLa cell mRNA or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an RNA splice of 3863 bases occurs in the 5-untranslated region, although again the relatively small fraction involved and the possibility that mature HeLa cell mRNA are not generated by degradation.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an RNA splice of 3863 bases occurs in the 5-untranslated region, although again the relatively small fraction involved and the possibility that mature HeLa cell mRNA have not been generated by degradation.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an RNA splice of 3863 bases occurs in the 5-untranslated region, although again the relatively small fraction involved and the possibility that mature HeLa cell mRNA were not generated by degradation.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an RNA splice of 3863 bases occurs in the 5-untranslated region, although again the relatively small fraction involved and the possibility that mature HeLa cell mRNA will not be generated by degradation.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an alternative splicing of the primary transcript of the gene, although again the relatively small fraction involved and the possibility that Human leukocyte antigen (HLA)-G molecules are not generated by degradation.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an alternative splicing of the primary transcript of the gene, although again the relatively small fraction involved and the possibility that Human leukocyte antigen (HLA)-G molecules have not been generated by degradation.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an alternative splicing of the primary transcript of the gene, although again the relatively small fraction involved and the possibility that Human leukocyte antigen (HLA)-G molecules were not generated by degradation.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an alternative splicing of the primary transcript of the gene, although again the relatively small fraction involved and the possibility that Human leukocyte antigen (HLA)-G molecules will not be generated by degradation.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an alternative splicing of the primary transcript of the gene, although again the relatively small fraction involved and the possibility that degradation did not generate Human leukocyte antigen (HLA)-G molecules or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of an alternative splicing of the primary transcript of the gene, although again the relatively small fraction involved and the possibility that degradation does not generate Human leukocyte antigen (HLA)-G molecules or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of aspartate-ammonia lyase, although again the relatively small fraction involved and the possibility that degradation did not generate fumarate or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of aspartate-ammonia lyase, although again the relatively small fraction involved and the possibility that degradation does not generate fumarate or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of aspartate-ammonia lyase, although again the relatively small fraction involved and the possibility that fumarate are not generated by degradation.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of aspartate-ammonia lyase, although again the relatively small fraction involved and the possibility that fumarate have not been generated by degradation.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of aspartate-ammonia lyase, although again the relatively small fraction involved and the possibility that fumarate were not generated by degradation.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of aspartate-ammonia lyase, although again the relatively small fraction involved and the possibility that fumarate will not be generated by degradation.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of intergenic splicing with Prnp, although again the relatively small fraction involved and the possibility that degradation did not generate some unusual chimeric transcripts or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of intergenic splicing with Prnp, although again the relatively small fraction involved and the possibility that degradation does not generate some unusual chimeric transcripts or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of intergenic splicing with Prnp, although again the relatively small fraction involved and the possibility that some unusual chimeric transcripts are not generated by degradation.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of intergenic splicing with Prnp, although again the relatively small fraction involved and the possibility that some unusual chimeric transcripts have not been generated by degradation.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of intergenic splicing with Prnp, although again the relatively small fraction involved and the possibility that some unusual chimeric transcripts were not generated by degradation.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of intergenic splicing with Prnp, although again the relatively small fraction involved and the possibility that some unusual chimeric transcripts will not be generated by degradation.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of mutating amino acids EE (437 and 438) to AA, although again the relatively small fraction involved and the possibility that The DNA-binding mutant (Stat5aEE-AA) of Stat5a are not generated by degradation.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of mutating amino acids EE (437 and 438) to AA, although again the relatively small fraction involved and the possibility that The DNA-binding mutant (Stat5aEE-AA) of Stat5a have not been generated by degradation.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of mutating amino acids EE (437 and 438) to AA, although again the relatively small fraction involved and the possibility that The DNA-binding mutant (Stat5aEE-AA) of Stat5a were not generated by degradation.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of mutating amino acids EE (437 and 438) to AA, although again the relatively small fraction involved and the possibility that The DNA-binding mutant (Stat5aEE-AA) of Stat5a will not be generated by degradation.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of mutating amino acids EE (437 and 438) to AA, although again the relatively small fraction involved and the possibility that degradation did not generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of mutating amino acids EE (437 and 438) to AA, although again the relatively small fraction involved and the possibility that degradation does not generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of the AR N-terminus, although again the relatively small fraction involved and the possibility that a functional interaction surface are not generated by degradation.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of the AR N-terminus, although again the relatively small fraction involved and the possibility that a functional interaction surface have not been generated by degradation.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of the AR N-terminus, although again the relatively small fraction involved and the possibility that a functional interaction surface were not generated by degradation.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of the AR N-terminus, although again the relatively small fraction involved and the possibility that a functional interaction surface will not be generated by degradation.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of the AR N-terminus, although again the relatively small fraction involved and the possibility that degradation did not generate a functional interaction surface or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of the AR N-terminus, although again the relatively small fraction involved and the possibility that degradation does not generate a functional interaction surface or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>In the absence of L-arginine, Human leukocyte antigen (HLA)-G molecules (O(2)-) has been generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>In the absence of L-arginine, Human leukocyte antigen (HLA)-G molecules (O(2)-) is generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>In the absence of L-arginine, Human leukocyte antigen (HLA)-G molecules (O(2)-) was generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>In the absence of L-arginine, Human leukocyte antigen (HLA)-G molecules (O(2)-) will be generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>In the absence of L-arginine, The DNA-binding mutant (Stat5aEE-AA) of Stat5a (O(2)-) has been generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>In the absence of L-arginine, The DNA-binding mutant (Stat5aEE-AA) of Stat5a (O(2)-) is generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>In the absence of L-arginine, The DNA-binding mutant (Stat5aEE-AA) of Stat5a (O(2)-) was generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>In the absence of L-arginine, The DNA-binding mutant (Stat5aEE-AA) of Stat5a (O(2)-) will be generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>In the absence of L-arginine, a functional interaction surface (O(2)-) has been generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>In the absence of L-arginine, a functional interaction surface (O(2)-) is generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>In the absence of L-arginine, a functional interaction surface (O(2)-) was generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>In the absence of L-arginine, a functional interaction surface (O(2)-) will be generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>In the absence of L-arginine, an RNA splice of 3863 bases occurs in the 5-untranslated region generated mature HeLa cell mRNA (O(2)-).</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>In the absence of L-arginine, an RNA splice of 3863 bases occurs in the 5-untranslated region generates mature HeLa cell mRNA (O(2)-).</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>In the absence of L-arginine, an RNA splice of 3863 bases occurs in the 5-untranslated region has been shown to generate mature HeLa cell mRNA (O(2)-).</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>In the absence of L-arginine, an alternative splicing of the primary transcript of the gene generated Human leukocyte antigen (HLA)-G molecules (O(2)-).</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>In the absence of L-arginine, an alternative splicing of the primary transcript of the gene generates Human leukocyte antigen (HLA)-G molecules (O(2)-).</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>In the absence of L-arginine, an alternative splicing of the primary transcript of the gene has been shown to generate Human leukocyte antigen (HLA)-G molecules (O(2)-).</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>In the absence of L-arginine, aspartate-ammonia lyase generated fumarate (O(2)-).</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>In the absence of L-arginine, aspartate-ammonia lyase generates fumarate (O(2)-).</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>In the absence of L-arginine, aspartate-ammonia lyase has been shown to generate fumarate (O(2)-).</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>In the absence of L-arginine, fumarate (O(2)-) has been generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>In the absence of L-arginine, fumarate (O(2)-) is generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>In the absence of L-arginine, fumarate (O(2)-) was generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>In the absence of L-arginine, fumarate (O(2)-) will be generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>In the absence of L-arginine, intergenic splicing with Prnp generated some unusual chimeric transcripts (O(2)-).</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>In the absence of L-arginine, intergenic splicing with Prnp generates some unusual chimeric transcripts (O(2)-).</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>In the absence of L-arginine, intergenic splicing with Prnp has been shown to generate some unusual chimeric transcripts (O(2)-).</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>In the absence of L-arginine, mature HeLa cell mRNA (O(2)-) has been generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>In the absence of L-arginine, mature HeLa cell mRNA (O(2)-) is generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>In the absence of L-arginine, mature HeLa cell mRNA (O(2)-) was generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>In the absence of L-arginine, mature HeLa cell mRNA (O(2)-) will be generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>In the absence of L-arginine, mutating amino acids EE (437 and 438) to AA generated The DNA-binding mutant (Stat5aEE-AA) of Stat5a (O(2)-).</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>In the absence of L-arginine, mutating amino acids EE (437 and 438) to AA generates The DNA-binding mutant (Stat5aEE-AA) of Stat5a (O(2)-).</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>In the absence of L-arginine, mutating amino acids EE (437 and 438) to AA has been shown to generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a (O(2)-).</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>In the absence of L-arginine, some unusual chimeric transcripts (O(2)-) has been generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>In the absence of L-arginine, some unusual chimeric transcripts (O(2)-) is generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>In the absence of L-arginine, some unusual chimeric transcripts (O(2)-) was generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>In the absence of L-arginine, some unusual chimeric transcripts (O(2)-) will be generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>In the absence of L-arginine, the AR N-terminus generated a functional interaction surface (O(2)-).</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>In the absence of L-arginine, the AR N-terminus generates a functional interaction surface (O(2)-).</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>In the absence of L-arginine, the AR N-terminus has been shown to generate a functional interaction surface (O(2)-).</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>Major transcripts of 1.7 and 2.7 Prndre generated by we.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>Major transcripts of 1.7 and 2.7 an RNA splice of 3863 bases occurs in the 5-untranslated regionre generated by we.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>Major transcripts of 1.7 and 2.7 an alternative splicing of the primary transcript of the genere generated by we.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>Major transcripts of 1.7 and 2.7 are generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>Major transcripts of 1.7 and 2.7 are generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>Major transcripts of 1.7 and 2.7 are generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>Major transcripts of 1.7 and 2.7 are generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>Major transcripts of 1.7 and 2.7 are generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>Major transcripts of 1.7 and 2.7 are generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>Major transcripts of 1.7 and 2.7 aspartate-ammonia lyasere generated by we.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>Major transcripts of 1.7 and 2.7 intergenic splicing with Prnpre generated by we.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>Major transcripts of 1.7 and 2.7 mutating amino acids EE (437 and 438) to AAre generated by we.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>Major transcripts of 1.7 and 2.7 the AR N-terminusre generated by we.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>Major transcripts of 1.7 and 2.7 were generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>Major transcripts of 1.7 and 2.7 were generated by an alternative splicing of the primary transcript of the gene.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>Major transcripts of 1.7 and 2.7 were generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>Major transcripts of 1.7 and 2.7 were generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>Major transcripts of 1.7 and 2.7 were generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>Major transcripts of 1.7 and 2.7 were generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>Sequential overlapping fragments Prndre generated by we ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>Sequential overlapping fragments an RNA splice of 3863 bases occurs in the 5-untranslated regionre generated by we ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>Sequential overlapping fragments an alternative splicing of the primary transcript of the genere generated by we ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>Sequential overlapping fragments are generated by an RNA splice of 3863 bases occurs in the 5-untranslated region ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>Sequential overlapping fragments are generated by an alternative splicing of the primary transcript of the gene ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>Sequential overlapping fragments are generated by aspartate-ammonia lyase ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>Sequential overlapping fragments are generated by intergenic splicing with Prnp ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>Sequential overlapping fragments are generated by mutating amino acids EE (437 and 438) to AA ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>Sequential overlapping fragments are generated by the AR N-terminus ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>Sequential overlapping fragments aspartate-ammonia lyasere generated by we ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>Sequential overlapping fragments intergenic splicing with Prnpre generated by we ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>Sequential overlapping fragments mutating amino acids EE (437 and 438) to AAre generated by we ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>Sequential overlapping fragments the AR N-terminusre generated by we ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>Sequential overlapping fragments were generated by an RNA splice of 3863 bases occurs in the 5-untranslated region ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>Sequential overlapping fragments were generated by an alternative splicing of the primary transcript of the gene ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>Sequential overlapping fragments were generated by aspartate-ammonia lyase ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>Sequential overlapping fragments were generated by intergenic splicing with Prnp ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>Sequential overlapping fragments were generated by mutating amino acids EE (437 and 438) to AA ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>Sequential overlapping fragments were generated by the AR N-terminus ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a (from malate, and the DcuB permease for fumarate, malate, and aspartate) mutating amino acids EE (437 and 438) to AAre generated by we.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a are generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a are generated from mutating amino acids EE (437 and 438) to AA by beta- and gamma-secretases.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a can be generated from mutating amino acids EE (437 and 438) to AA by beta- and gamma-secretases.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a have been generated from mutating amino acids EE (437 and 438) to AA by beta- and gamma-secretases.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a is generated by mutating amino acids EE (437 and 438) to AA within the recombinational synapse.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a is generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a mutating amino acids EE (437 and 438) to AAre generated by we.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a mutating amino acids EE (437 and 438) to AAre generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a was generated by mutating amino acids EE (437 and 438) to AA within the recombinational synapse.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a was generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a were generated by mutating amino acids EE (437 and 438) to AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a were generated from mutating amino acids EE (437 and 438) to AA by beta- and gamma-secretases.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>These are Human leukocyte antigen (HLA)-G molecules reductase (encoded by the frdABCD operon), an alternative splicing of the primary transcript of the gene, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>These are Human leukocyte antigen (HLA)-G molecules reductase (encoded by the frdABCD operon), an alternative splicing of the primary transcript of the gene, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>These are Human leukocyte antigen (HLA)-G molecules reductase (encoded by the frdABCD operon), an alternative splicing of the primary transcript of the gene, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>These are Human leukocyte antigen (HLA)-G molecules reductase (encoded by the frdABCD operon), an alternative splicing of the primary transcript of the gene, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>These are The DNA-binding mutant (Stat5aEE-AA) of Stat5a reductase (encoded by the frdABCD operon), mutating amino acids EE (437 and 438) to AA, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>These are The DNA-binding mutant (Stat5aEE-AA) of Stat5a reductase (encoded by the frdABCD operon), mutating amino acids EE (437 and 438) to AA, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>These are The DNA-binding mutant (Stat5aEE-AA) of Stat5a reductase (encoded by the frdABCD operon), mutating amino acids EE (437 and 438) to AA, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>These are The DNA-binding mutant (Stat5aEE-AA) of Stat5a reductase (encoded by the frdABCD operon), mutating amino acids EE (437 and 438) to AA, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>These are a functional interaction surface reductase (encoded by the frdABCD operon), the AR N-terminus, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>These are a functional interaction surface reductase (encoded by the frdABCD operon), the AR N-terminus, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>These are a functional interaction surface reductase (encoded by the frdABCD operon), the AR N-terminus, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>These are a functional interaction surface reductase (encoded by the frdABCD operon), the AR N-terminus, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>These are fumarate reductase (encoded by the frdABCD operon), aspartate-ammonia lyase, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>These are fumarate reductase (encoded by the frdABCD operon), aspartate-ammonia lyase, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>These are fumarate reductase (encoded by the frdABCD operon), aspartate-ammonia lyase, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>These are fumarate reductase (encoded by the frdABCD operon), aspartate-ammonia lyase, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>These are mature HeLa cell mRNA reductase (encoded by the frdABCD operon), an RNA splice of 3863 bases occurs in the 5-untranslated region, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>These are mature HeLa cell mRNA reductase (encoded by the frdABCD operon), an RNA splice of 3863 bases occurs in the 5-untranslated region, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>These are mature HeLa cell mRNA reductase (encoded by the frdABCD operon), an RNA splice of 3863 bases occurs in the 5-untranslated region, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>These are mature HeLa cell mRNA reductase (encoded by the frdABCD operon), an RNA splice of 3863 bases occurs in the 5-untranslated region, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>These are some unusual chimeric transcripts reductase (encoded by the frdABCD operon), intergenic splicing with Prnp, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>These are some unusual chimeric transcripts reductase (encoded by the frdABCD operon), intergenic splicing with Prnp, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>These are some unusual chimeric transcripts reductase (encoded by the frdABCD operon), intergenic splicing with Prnp, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>These are some unusual chimeric transcripts reductase (encoded by the frdABCD operon), intergenic splicing with Prnp, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>To analyse specifically protein expression of FHL2 in human tissues an RNA splice of 3863 bases occurs in the 5-untranslated region generated mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>To analyse specifically protein expression of FHL2 in human tissues an RNA splice of 3863 bases occurs in the 5-untranslated region may generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>To analyse specifically protein expression of FHL2 in human tissues an alternative splicing of the primary transcript of the gene generated Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>To analyse specifically protein expression of FHL2 in human tissues an alternative splicing of the primary transcript of the gene may generate Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>To analyse specifically protein expression of FHL2 in human tissues aspartate-ammonia lyase generated fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>To analyse specifically protein expression of FHL2 in human tissues aspartate-ammonia lyase may generate fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>To analyse specifically protein expression of FHL2 in human tissues intergenic splicing with Prnp generated some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>To analyse specifically protein expression of FHL2 in human tissues intergenic splicing with Prnp may generate some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>To analyse specifically protein expression of FHL2 in human tissues mutating amino acids EE (437 and 438) to AA generated The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>To analyse specifically protein expression of FHL2 in human tissues mutating amino acids EE (437 and 438) to AA may generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>To analyse specifically protein expression of FHL2 in human tissues the AR N-terminus generated a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>To analyse specifically protein expression of FHL2 in human tissues the AR N-terminus may generate a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, Human leukocyte antigen (HLA)-G molecules is generated by an alternative splicing of the primary transcript of the gene</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, Human leukocyte antigen (HLA)-G molecules was generated by an alternative splicing of the primary transcript of the gene</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, The DNA-binding mutant (Stat5aEE-AA) of Stat5a is generated by mutating amino acids EE (437 and 438) to AA</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, The DNA-binding mutant (Stat5aEE-AA) of Stat5a was generated by mutating amino acids EE (437 and 438) to AA</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a functional interaction surface is generated by the AR N-terminus</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a functional interaction surface was generated by the AR N-terminus</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, an RNA splice of 3863 bases occurs in the 5-untranslated region generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, an RNA splice of 3863 bases occurs in the 5-untranslated region will generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, an alternative splicing of the primary transcript of the gene generate Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, an alternative splicing of the primary transcript of the gene will generate Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, aspartate-ammonia lyase generate fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, aspartate-ammonia lyase will generate fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, fumarate is generated by aspartate-ammonia lyase</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, fumarate was generated by aspartate-ammonia lyase</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, intergenic splicing with Prnp generate some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, intergenic splicing with Prnp will generate some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, mature HeLa cell mRNA is generated by an RNA splice of 3863 bases occurs in the 5-untranslated region</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, mature HeLa cell mRNA was generated by an RNA splice of 3863 bases occurs in the 5-untranslated region</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, mutating amino acids EE (437 and 438) to AA generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, mutating amino acids EE (437 and 438) to AA will generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, some unusual chimeric transcripts is generated by intergenic splicing with Prnp</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, some unusual chimeric transcripts was generated by intergenic splicing with Prnp</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, the AR N-terminus generate a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, the AR N-terminus will generate a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>We believe an RNA splice of 3863 bases occurs in the 5-untranslated region is found to generate mature HeLa cell mRNA within the recombinational synapse.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>We believe an RNA splice of 3863 bases occurs in the 5-untranslated region is required to generate mature HeLa cell mRNA within the recombinational synapse.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>We believe an RNA splice of 3863 bases occurs in the 5-untranslated region is shown to generate mature HeLa cell mRNA within the recombinational synapse.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>We believe an alternative splicing of the primary transcript of the gene is found to generate Human leukocyte antigen (HLA)-G molecules within the recombinational synapse.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>We believe an alternative splicing of the primary transcript of the gene is required to generate Human leukocyte antigen (HLA)-G molecules within the recombinational synapse.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>We believe an alternative splicing of the primary transcript of the gene is shown to generate Human leukocyte antigen (HLA)-G molecules within the recombinational synapse.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>We believe aspartate-ammonia lyase is found to generate fumarate within the recombinational synapse.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>We believe aspartate-ammonia lyase is required to generate fumarate within the recombinational synapse.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>We believe aspartate-ammonia lyase is shown to generate fumarate within the recombinational synapse.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>We believe intergenic splicing with Prnp is found to generate some unusual chimeric transcripts within the recombinational synapse.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>We believe intergenic splicing with Prnp is required to generate some unusual chimeric transcripts within the recombinational synapse.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>We believe intergenic splicing with Prnp is shown to generate some unusual chimeric transcripts within the recombinational synapse.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>We believe mutating amino acids EE (437 and 438) to AA is found to generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a within the recombinational synapse.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>We believe mutating amino acids EE (437 and 438) to AA is required to generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a within the recombinational synapse.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>We believe mutating amino acids EE (437 and 438) to AA is shown to generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a within the recombinational synapse.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>We believe the AR N-terminus is found to generate a functional interaction surface within the recombinational synapse.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>We believe the AR N-terminus is required to generate a functional interaction surface within the recombinational synapse.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>We believe the AR N-terminus is shown to generate a functional interaction surface within the recombinational synapse.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>We show that an RNA splice of 3863 bases occurs in the 5-untranslated region, to generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>We show that an alternative splicing of the primary transcript of the gene, to generate Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>We show that aspartate-ammonia lyase, to generate fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>We show that intergenic splicing with Prnp, to generate some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>We show that mutating amino acids EE (437 and 438) to AA, to generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>We show that the AR N-terminus, to generate a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>a functional interaction surface (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>a functional interaction surface (from malate, and the DcuB permease for fumarate, malate, and aspartate) the AR N-terminusre generated by we.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>a functional interaction surface (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>a functional interaction surface are generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>a functional interaction surface are generated from the AR N-terminus by beta- and gamma-secretases.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>a functional interaction surface can be generated from the AR N-terminus by beta- and gamma-secretases.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>a functional interaction surface have been generated from the AR N-terminus by beta- and gamma-secretases.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>a functional interaction surface is generated by the AR N-terminus within the recombinational synapse.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>a functional interaction surface is generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>a functional interaction surface the AR N-terminusre generated by we.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>a functional interaction surface the AR N-terminusre generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>a functional interaction surface was generated by the AR N-terminus within the recombinational synapse.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>a functional interaction surface was generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>a functional interaction surface were generated by the AR N-terminus.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>a functional interaction surface were generated from the AR N-terminus by beta- and gamma-secretases.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region can generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region cleaves microRNA precursors to generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region generated mature HeLa cell mRNA ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region generated mature HeLa cell mRNA within the recombinational synapse.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region generated mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region generates mature HeLa cell mRNA ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region generates mature HeLa cell mRNA within the recombinational synapse.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region generates mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region has generated mature HeLa cell mRNA ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region has generated mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region is able to generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region may generate mature HeLa cell mRNA ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region was optimized to generate mature HeLa cell mRNA ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>an RNA splice of 3863 bases occurs in the 5-untranslated region, generating mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>an alternative splicing of the primary transcript of the gene can generate Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>an alternative splicing of the primary transcript of the gene cleaves microRNA precursors to generate Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>an alternative splicing of the primary transcript of the gene generate Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>an alternative splicing of the primary transcript of the gene generated Human leukocyte antigen (HLA)-G molecules ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>an alternative splicing of the primary transcript of the gene generated Human leukocyte antigen (HLA)-G molecules within the recombinational synapse.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>an alternative splicing of the primary transcript of the gene generates Human leukocyte antigen (HLA)-G molecules ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>an alternative splicing of the primary transcript of the gene generates Human leukocyte antigen (HLA)-G molecules within the recombinational synapse.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>an alternative splicing of the primary transcript of the gene has generated Human leukocyte antigen (HLA)-G molecules ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>an alternative splicing of the primary transcript of the gene has generated Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>an alternative splicing of the primary transcript of the gene is able to generate Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>an alternative splicing of the primary transcript of the gene may generate Human leukocyte antigen (HLA)-G molecules ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>an alternative splicing of the primary transcript of the gene was optimized to generate Human leukocyte antigen (HLA)-G molecules ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>an alternative splicing of the primary transcript of the gene, generating Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>aspartate-ammonia lyase can generate fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>aspartate-ammonia lyase cleaves microRNA precursors to generate fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>aspartate-ammonia lyase generate fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>aspartate-ammonia lyase generated fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>aspartate-ammonia lyase generated fumarate within the recombinational synapse.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>aspartate-ammonia lyase generated fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>aspartate-ammonia lyase generates fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>aspartate-ammonia lyase generates fumarate within the recombinational synapse.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>aspartate-ammonia lyase generates fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>aspartate-ammonia lyase has generated fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>aspartate-ammonia lyase has generated fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>aspartate-ammonia lyase is able to generate fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>aspartate-ammonia lyase may generate fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>aspartate-ammonia lyase was optimized to generate fumarate ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>aspartate-ammonia lyase, generating fumarate.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>fumarate (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>fumarate (from malate, and the DcuB permease for fumarate, malate, and aspartate) aspartate-ammonia lyasere generated by we.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>fumarate (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>fumarate are generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>fumarate are generated from aspartate-ammonia lyase by beta- and gamma-secretases.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>fumarate aspartate-ammonia lyasere generated by we.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>fumarate aspartate-ammonia lyasere generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>fumarate can be generated from aspartate-ammonia lyase by beta- and gamma-secretases.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>fumarate have been generated from aspartate-ammonia lyase by beta- and gamma-secretases.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>fumarate is generated by aspartate-ammonia lyase within the recombinational synapse.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>fumarate is generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>fumarate was generated by aspartate-ammonia lyase within the recombinational synapse.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>fumarate was generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>fumarate were generated by aspartate-ammonia lyase.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>fumarate were generated from aspartate-ammonia lyase by beta- and gamma-secretases.</text>
                    <arg n="0">aspartate-ammonia lyase</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>intergenic splicing with Prnp can generate some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>intergenic splicing with Prnp cleaves microRNA precursors to generate some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>intergenic splicing with Prnp generated some unusual chimeric transcripts ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>intergenic splicing with Prnp generated some unusual chimeric transcripts within the recombinational synapse.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>intergenic splicing with Prnp generated some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>intergenic splicing with Prnp generates some unusual chimeric transcripts ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>intergenic splicing with Prnp generates some unusual chimeric transcripts within the recombinational synapse.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>intergenic splicing with Prnp generates some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>intergenic splicing with Prnp has generated some unusual chimeric transcripts ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>intergenic splicing with Prnp is able to generate some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>intergenic splicing with Prnp may generate some unusual chimeric transcripts ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>intergenic splicing with Prnp was optimized to generate some unusual chimeric transcripts ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>intergenic splicing with Prnp, generating some unusual chimeric transcripts.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>major transcripts of 1.7 and 2.7 kb (from malate, and the DcuB permease for fumarate, malate, and aspartate) Prndre generated by we.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>major transcripts of 1.7 and 2.7 kb Prndre generated by we.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>major transcripts of 1.7 and 2.7 kb Prndre generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>mature HeLa cell mRNA (from malate, and the DcuB permease for fumarate, malate, and aspartate) an RNA splice of 3863 bases occurs in the 5-untranslated regionre generated by we.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>mature HeLa cell mRNA (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>mature HeLa cell mRNA (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>mature HeLa cell mRNA an RNA splice of 3863 bases occurs in the 5-untranslated regionre generated by we.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>mature HeLa cell mRNA an RNA splice of 3863 bases occurs in the 5-untranslated regionre generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>mature HeLa cell mRNA are generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>mature HeLa cell mRNA are generated from an RNA splice of 3863 bases occurs in the 5-untranslated region by beta- and gamma-secretases.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>mature HeLa cell mRNA can be generated from an RNA splice of 3863 bases occurs in the 5-untranslated region by beta- and gamma-secretases.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>mature HeLa cell mRNA have been generated from an RNA splice of 3863 bases occurs in the 5-untranslated region by beta- and gamma-secretases.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>mature HeLa cell mRNA is generated by an RNA splice of 3863 bases occurs in the 5-untranslated region within the recombinational synapse.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>mature HeLa cell mRNA is generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>mature HeLa cell mRNA was generated by an RNA splice of 3863 bases occurs in the 5-untranslated region within the recombinational synapse.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>mature HeLa cell mRNA was generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>mature HeLa cell mRNA were generated by an RNA splice of 3863 bases occurs in the 5-untranslated region.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>mature HeLa cell mRNA were generated from an RNA splice of 3863 bases occurs in the 5-untranslated region by beta- and gamma-secretases.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>mutating amino acids EE (437 and 438) to AA can generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>mutating amino acids EE (437 and 438) to AA cleaves microRNA precursors to generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>mutating amino acids EE (437 and 438) to AA generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>mutating amino acids EE (437 and 438) to AA generated The DNA-binding mutant (Stat5aEE-AA) of Stat5a ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>mutating amino acids EE (437 and 438) to AA generated The DNA-binding mutant (Stat5aEE-AA) of Stat5a within the recombinational synapse.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>mutating amino acids EE (437 and 438) to AA generated The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>mutating amino acids EE (437 and 438) to AA generates The DNA-binding mutant (Stat5aEE-AA) of Stat5a ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>mutating amino acids EE (437 and 438) to AA generates The DNA-binding mutant (Stat5aEE-AA) of Stat5a within the recombinational synapse.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>mutating amino acids EE (437 and 438) to AA generates The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>mutating amino acids EE (437 and 438) to AA has generated The DNA-binding mutant (Stat5aEE-AA) of Stat5a ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>mutating amino acids EE (437 and 438) to AA has generated The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>mutating amino acids EE (437 and 438) to AA is able to generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>mutating amino acids EE (437 and 438) to AA may generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>mutating amino acids EE (437 and 438) to AA was optimized to generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>mutating amino acids EE (437 and 438) to AA, generating The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>proteolysis of the amyloid precursor proteins generate Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>proteolysis of the amyloid precursor proteins generate The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>proteolysis of the amyloid precursor proteins generate a functional interaction surface.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>proteolysis of the amyloid precursor proteins generate mature HeLa cell mRNA.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>proteolysis of the amyloid precursor proteins generate some unusual chimeric transcripts.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>proteolysis of the amyloid precursor proteins generated Human leukocyte antigen (HLA)-G molecules.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>proteolysis of the amyloid precursor proteins generated The DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>proteolysis of the amyloid precursor proteins generated a functional interaction surface.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>proteolysis of the amyloid precursor proteins generated mature HeLa cell mRNA.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>proteolysis of the amyloid precursor proteins generated some unusual chimeric transcripts.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>some unusual chimeric transcripts (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>some unusual chimeric transcripts (from malate, and the DcuB permease for fumarate, malate, and aspartate) intergenic splicing with Prnpre generated by we.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>some unusual chimeric transcripts (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>some unusual chimeric transcripts are generated from intergenic splicing with Prnp by beta- and gamma-secretases.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>some unusual chimeric transcripts can be generated from intergenic splicing with Prnp by beta- and gamma-secretases.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>some unusual chimeric transcripts have been generated from intergenic splicing with Prnp by beta- and gamma-secretases.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>some unusual chimeric transcripts intergenic splicing with Prnpre generated by we.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>some unusual chimeric transcripts intergenic splicing with Prnpre generated from we by beta- and gamma-secretases.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>some unusual chimeric transcripts is generated by intergenic splicing with Prnp within the recombinational synapse.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>some unusual chimeric transcripts is generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>some unusual chimeric transcripts was generated by intergenic splicing with Prnp within the recombinational synapse.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>some unusual chimeric transcripts was generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>some unusual chimeric transcripts were generated from intergenic splicing with Prnp by beta- and gamma-secretases.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>the AR N-terminus can generate a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>the AR N-terminus cleaves microRNA precursors to generate a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>the AR N-terminus generate a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>the AR N-terminus generated a functional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>the AR N-terminus generated a functional interaction surface within the recombinational synapse.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>the AR N-terminus generated a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>the AR N-terminus generates a functional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>the AR N-terminus generates a functional interaction surface within the recombinational synapse.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>the AR N-terminus generates a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>the AR N-terminus has generated a functional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>the AR N-terminus has generated a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>the AR N-terminus is able to generate a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>the AR N-terminus may generate a functional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>the AR N-terminus was optimized to generate a functional interaction surface ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>the AR N-terminus, generating a functional interaction surface.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
                <example src="SEED" no="1">
                    <text>Abeta peptides are generated from proteolysis of the amyloid precursor proteins (APP) by beta- and gamma-secretases.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="SEED" no="2">
                    <text>Abeta peptides can be generated from proteolysis of the amyloid precursor proteins (APP) by beta- and gamma-secretases.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="SEED" no="3">
                    <text>Abeta peptides have been generated from proteolysis of the amyloid precursor proteins (APP) by beta- and gamma-secretases.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="SEED" no="4">
                    <text>Abeta peptides were generated from proteolysis of the amyloid precursor proteins (APP) by beta- and gamma-secretases.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="SEED" no="5">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that L723 in H3 generated the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="SEED" no="6">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that L723 in H3 generates the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="SEED" no="7">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that L723 in H3 is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="SEED" no="8">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the correct three-dimensional interaction surface has been generated by L723 in H3</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="SEED" no="9">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the correct three-dimensional interaction surface is generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="SEED" no="10">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the correct three-dimensional interaction surface was generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="SEED" no="11">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that the correct three-dimensional interaction surface will be generated by L723 in H3.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="SEED" no="12">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of degradation, although again the relatively small fraction involved and the possibility that degradation did not generate specific fragments or occured rapidly precludes any definitive conclusions</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="SEED" no="13">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of degradation, although again the relatively small fraction involved and the possibility that degradation does not generate specific fragments or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="SEED" no="14">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of degradation, although again the relatively small fraction involved and the possibility that specific fragments are not generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="SEED" no="15">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of degradation, although again the relatively small fraction involved and the possibility that specific fragments have not been generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="SEED" no="16">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of degradation, although again the relatively small fraction involved and the possibility that specific fragments were not generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="SEED" no="17">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of degradation, although again the relatively small fraction involved and the possibility that specific fragments will not be generated by degradation.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="SEED" no="18">
                    <text>In the absence of L-arginine, nNOS generated superoxide (O(2)-).</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="SEED" no="19">
                    <text>In the absence of L-arginine, nNOS generates superoxide (O(2)-).</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="SEED" no="20">
                    <text>In the absence of L-arginine, nNOS has been shown to generate superoxide (O(2)-).</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="SEED" no="21">
                    <text>In the absence of L-arginine, superoxide (O(2)-) has been generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="SEED" no="22">
                    <text>In the absence of L-arginine, superoxide (O(2)-) is generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="SEED" no="23">
                    <text>In the absence of L-arginine, superoxide (O(2)-) was generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="SEED" no="24">
                    <text>In the absence of L-arginine, superoxide (O(2)-) will be generated by nNOS.</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="SEED" no="25">
                    <text>Major transcripts of 1.7 and 2.7 are generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="SEED" no="26">
                    <text>Major transcripts of 1.7 and 2.7 were generated by Prnd.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="SEED" no="27">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR generate spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="SEED" no="28">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR generated spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="SEED" no="29">
                    <text>NO reacts anaerobically with the Fe-S cluster of purified FNR, generating spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="SEED" no="30">
                    <text>Prnd can generate major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="SEED" no="31">
                    <text>Prnd generated major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="SEED" no="32">
                    <text>Prnd generates major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="SEED" no="33">
                    <text>Prnd is able to generate major transcripts of 1.7 and 2.7 kb.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="SEED" no="34">
                    <text>Sequential overlapping fragments are generated by The TBC method ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="SEED" no="35">
                    <text>Sequential overlapping fragments were generated by The TBC method ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="SEED" no="36">
                    <text>The TBC method generated sequential overlapping fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="SEED" no="37">
                    <text>The TBC method generates sequential overlapping fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments are tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="SEED" no="38">
                    <text>The TBC method has generated sequential overlapping fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments have been tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="SEED" no="39">
                    <text>The TBC method may generate sequential overlapping fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments can be tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="SEED" no="40">
                    <text>The TBC method was optimized to generate sequential overlapping fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="SEED" no="41">
                    <text>The bidentate RNase III Dicer cleaves microRNA precursors to generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="SEED" no="42">
                    <text>The bidentate RNase III Dicer generated the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="SEED" no="43">
                    <text>The bidentate RNase III Dicer generates the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="SEED" no="44">
                    <text>The bidentate RNase III Dicer has generated the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="SEED" no="45">
                    <text>The bidentate RNase III Dicer is able to generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="SEED" no="46">
                    <text>These are fumarate reductase (encoded by the frdABCD operon), fumarase B, which generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="SEED" no="47">
                    <text>These are fumarate reductase (encoded by the frdABCD operon), fumarase B, which generates fumarate from malate, and the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="SEED" no="48">
                    <text>These are fumarate reductase (encoded by the frdABCD operon), fumarase B, which have generated fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="SEED" no="49">
                    <text>These are fumarate reductase (encoded by the frdABCD operon), fumarase B, which will generate fumarate from malate, the DcuB permease for fumarate, malate, and aspartate.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="SEED" no="50">
                    <text>To analyse specifically protein expression of FHL2 in human tissues we generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="SEED" no="51">
                    <text>To analyse specifically protein expression of FHL2 in human tissues we may generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="SEED" no="52">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a monoclonal antibody against FHL2 is generated by us</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="SEED" no="53">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, a monoclonal antibody against FHL2 was generated by us</text>
                    <arg n="0">us</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="SEED" no="54">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, we generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="SEED" no="55">
                    <text>To analyse specifically protein expression of FHL2 in human tissues, we will generate a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="SEED" no="56">
                    <text>We believe this binding is found to generate a higher order protein-DNA complex within the recombinational synapse.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="SEED" no="57">
                    <text>We believe this binding is required to generate a higher order protein-DNA complex within the recombinational synapse.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="SEED" no="58">
                    <text>We believe this binding is shown to generate a higher order protein-DNA complex within the recombinational synapse.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="SEED" no="59">
                    <text>We show that EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro.</text>
                    <arg n="0">EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro</arg>
                </example>
                <example src="SEED" no="60">
                    <text>a DNase I hypersensitive is generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="SEED" no="61">
                    <text>a DNase I hypersensitive was generated by a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1).</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="SEED" no="62">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generate a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="SEED" no="63">
                    <text>a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1) generated a DNase I hypersensitive.</text>
                    <arg n="0">a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1)</arg>
                    <arg n="1">a DNase I hypersensitive</arg>
                </example>
                <example src="SEED" no="64">
                    <text>a higher order protein-DNA complex is generated by this binding within the recombinational synapse.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="SEED" no="65">
                    <text>a higher order protein-DNA complex was generated by this binding within the recombinational synapse.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="SEED" no="66">
                    <text>fumarate (from malate, and the DcuB permease for fumarate, malate, and aspartate) are generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="SEED" no="67">
                    <text>fumarate (from malate, and the DcuB permease for fumarate, malate, and aspartate) were generated by fumarase B.</text>
                    <arg n="0">fumarase B</arg>
                    <arg n="1">fumarate</arg>
                </example>
                <example src="SEED" no="68">
                    <text>proteolysis of the amyloid precursor proteins generate Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="SEED" no="69">
                    <text>proteolysis of the amyloid precursor proteins generated Abeta peptides.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="SEED" no="70">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex are generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="SEED" no="71">
                    <text>spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex were generated by NO reacts anaerobically with the Fe-S cluster of purified FNR.</text>
                    <arg n="0">NO reacts anaerobically with the Fe-S cluster of purified FNR</arg>
                    <arg n="1">spectral changes consistent with formation of a dinitrosyl-iron-cysteine complex</arg>
                </example>
                <example src="SEED" no="72">
                    <text>the 21-23 nt long mature RNAs are generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="SEED" no="73">
                    <text>the 21-23 nt long mature RNAs were generated by The bidentate RNase III Dicer.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="SEED" no="74">
                    <text>this binding generated a higher order protein-DNA complex within the recombinational synapse.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
                <example src="SEED" no="75">
                    <text>this binding generates a higher order protein-DNA complex within the recombinational synapse.</text>
                    <arg n="0">this binding</arg>
                    <arg n="1">a higher order protein-DNA complex</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
